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CHAPTER 1
Introduction
The human pain experience, both experimental and clinical, is composed of three
dimensions (Gracely, McGrath, & Dubner, 1978; Price, Harkins, & Baker, 1987). The
sensory-discriminative dimension of pain permits the individual to localize the painful
stimulus, and to assess its intensity and physical properties. The affective-motivational
dimension encourages avoidance and recuperation via the perception of negative affect
associated with noxious stimulation. The cognitive-evaluative dimension induces an
appraisal of the meanings and consequences associated with painful sensations and
injury. These latter two dimensions interact to generate emotional disturbances such as
fear, anxiety, frustration and depression that contribute to the suffering and physical
disabilities of patients in chronic pain (Crombez, Vlaeyen, Heuts, & Lysens, 1999;
McCracken, Zayfert, & Gross, 1992; Sullivan, Reesor, Mikail, & Fisher, 1992; Waddell,
Newton, Henderson, Somerville, & Main, 1993; Wade, Dougherty, Hart, Rafii, & Price,
1992). Therefore, understanding the neurobiology that underlies the generation and
suppression of pain affect is of clinical importance and warrants intensive study.
The amygdala is a forebrain structure critical for providing affective salience to
sensory information for animals and humans (LeDoux, 2000).

Functional magnetic

resonance imaging studies in humans report that increased amygdala activation is
associated with fear and anxiety (Adolphs, Tranel, & Damasio, 1998; Critchley, Mathias,
& Dolan, 2002; Furmark, Fischer, Wik, Larsson, & Fredrikson, 1997; Tillfors, et al.,
2001) or exposure to threatening stimuli (Carlsson, et al., 2004; Carretie, Hinojosa,
Mercado, & Tapia, 2005; Isenberg, et al., 1999; Phelps, et al., 2001).

Similarly,
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amygdala activation is observed in fearful and anxious rats, or in rats exposed to
aversive and threatening stimuli (Adell, Casanovas, & Artigas, 1997; Duncan, Knapp, &
Breese, 1996; Figueiredo, Bodie, Tauchi, Dolgas, & Herman, 2003; Lehner, et al.,
2006). On the other hand, damage to the amygdala suppresses responding to aversive
and threatening stimuli in both humans and animals (Blanchard & Blanchard, 1972;
Borszcz & Leaton, 2003; Hebben, Corkin, Eichenbaum, & Shedlack, 1985; Jelasic,
1966). These findings indicate that the amygdala acts as the “threat detector” of the
brain. The amygdala processes stimuli that threaten the individual and contributes to
the execution of affective behaviors that permit the individual to cope with the threat
(Bernard & Bandler, 1998; LeDoux, 2000).
The prototypical threat to an individual is exposure to a noxious stimulus Within the
brain, the amygdaloid central nucleus (CeA) and basolateral complex (BLC; includes
lateral and basolateral subnuclei) receive nociceptive afferents via spinoamygdaloid
(Giesler, Katter, & Dado, 1994; Newman, Stevens, & Apkarian, 1996) and spinoparabrachio-amygdaloid pathways (Bernard & Besson, 1990; Ma & Peschanski, 1988),
directly from collaterals of the spinothalamic tract (Burstein & Potrebic, 1993), and
indirectly from spinoreticulothalamic and spinopontothalamic tracts via inputs relayed by
medial and intralaminar thalamic nuclei (Bourgeais, Gauriau, & Bernard, 2001; Krout &
Loewy, 2000; Petrovicky, 1990; Su & Bentivoglio, 1990; Volz, et al., 1990), and the
insular cortex (Shi & Davis, 1999). Noxious stimulation evokes neural activity in both
CeA and BLC (Bernard, Huang, & Besson, 1990; Romanski, Clugnet, Bordi, & LeDoux,
1993).
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In addition to nociceptive input, the BLC receives highly processed multimodal
sensory information from several cortical regions (visual, auditory, somatosensory and
olfactory cortices), as well as more direct but less processed sensory information from
the corresponding thalamic nuclei. The BLC is proposed to process these inputs and
allocate emotional salience to those that represent environmental threats. The outputs
of the BLC engage the defense circuit that enables the individual to respond to the
threat (McDonald, 1998; Pitkanen, 2000). The CeA is the major output sub-nucleus of
the amygdala and the CeA receives afferents from the BLC. Efferents from CeA to the
hypothalamus, periaqueductal gray, and medulla coordinate execution of defensive
behaviors designed to cope with threats (LeDoux, Iwata, Cicchetti, & Reis, 1988;
Petrovich, Canteras, & Swanson, 2001; Pitkanen, 2000).

Therefore, the CeA was

evaluated for its contribution to the production of pain affect in the present study.
1.1 Evidence for a Role of the Amygdala in Pain Processing
Case studies of patients that received ablations within the limbic forebrain
implicate the amygdala as an essential structure involved in the affective experience of
pain. The classic neurological patient H.M. received a bilateral resection of the medial
temporal lobe for the treatment of epilepsy, resulting in the ablation of several limbic
structures, including most of the amygdaloid complex (Corkin, Amaral, Gonzalez,
Johnson, & Hyman, 1997). H.M. subsequently suffered from a range of neurological
deficits, including anterograde amnesia, the inability to perceive odor quality, and most
relevant to the current investigation, the failure to identify painful stimuli and to withdraw
from such stimuli (Corkin, 1984; Hebben, et al., 1985). Hebben and colleagues (1985)
demonstrated that thermal stimulation of H.M.’s hand or chest, as compared to normal
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control patients and control patients with global amnesia, resulted in a failure to
perceive the stimulation as noxious as measured by withdrawal latency (Hebben, et al.,
1985).

Although these results implicate the ablated region (i.e., amygdala) in pain

sensation, H.M.’s inability to report internal states such as hunger and thirst and his
inability to feel discomfort from the applied noxious thermal stimulation suggests a
generalized deficit in affective responding.
In patients with trigeminal neuralgia, bilateral amygdalotomy reduces intractable
pain (Jelasic, 1966).

Patients reported moderate to intense pain during electrode

implantation and during injection of the lesioning material into the left or right
hemispheric amygdala.

Following the procedure, patients reported decreased pain

sensation and decreased pain affect to the neuralgia syndrome.

Brown (1977)

successfully treated intractable pain patients who experienced associated psychological
consequences (e.g., drug dependence and psychogenic fixation) with lesions of the
limbic system (Brown, 1977). Follow-up assessments of up to twenty years revealed
that the majority of patients (90.5%) experienced improvement as measured by pain
relief, requirement of medication, and ability to function at a job or in the home. These
case studies demonstrate that the amygdala and other forebrain structures process
nociceptive information, and most notably, mediate the affective dimension of the pain
experience.
In accordance with the findings from lesion studies, human neuroimaging studies
consistently reveal activation of the amygdala during noxious stimulation (Bingel, et al.,
2002; Kulkarni, et al., 2005). Bingel and colleagues (2002) reported that application of
noxious radiant stimuli via a thulium (Tm)-yttrium-aluminum-granate (YAG) laser to
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either the left or right hand of healthy participants evoked bilateral increases in the
blood-oxygen-level-dependence (BOLD) measure within the amygdala.

Bilateral

activation of the amygdala to a unilateral stimulus precludes amygdalar involvement in
the sensory-discriminative aspect of pain processing and rather supports a role of the
amygdala in the affective-motivational aspect of pain processing.

Further, healthy

participants instructed to attend to the unpleasantness associated with the application of
a noxious CO2 laser to the left dorsal forearm exhibited increases in regional cerebral
blood flow (rCBF) within the amygdala (Kulkarni, et al., 2005). Participants instructed to
attend to the location of the stimulus did exhibit a change in rCBF levels within the
amygdala. These results support the notion that the amygdala is involved in affectivemotivational processing of nociceptive information.

It should be noted that the

resolution of current imaging technology does not permit identification of the individual
amygdaloid nuclei activated in these studies. Recently, however, pain-evoked neural
activity was recorded in humans through electrodes implanted bilaterally in the medial
temporal lobe during the investigation of intractable epilepsy (Liu, et al., 2010).
Stimulation of the hand with a laser that selectively activated cutaneous nociceptors
produced evoked responses from CeA. Consistent with the results of neuroimaging
studies, pain-evoked responses in CeA were recorded bilaterally following stimulation of
either hand.
Fos is the protein product encoded by the c-Fos gene that is expressed following
neurotransmitter binding and membrane depolarization (Sheng & Greenberg, 1990),
and provides an indirect measure of neuronal activation. Fos expression is increased in
the amygdaloid complex following acute intra-plantar (i.pl.) formalin injection (Lei,
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Zhang, & Zhao, 2004) and in response to noxious peripheral stimulation of the tail via
hot water bath (Dai, Zhu, Li, Huang, & Xu, 1993). These studies do not discuss which
subnuclei of the amygdala exhibited increased Fos expression, however, examination of
the histological figures suggest primary labeling in the medial, lateral, basal, and central
nuclei.

Nakagawa and colleagues (2003) reported that i.pl. formalin injections

significantly increased Fos expression in the lateral and basolateral amygdala, but not
CeA, contralateral to the side of stimulus presentation. However, these investigators
observed that intraperitoneal (i.p.) administration of acetic acid elevated Fos expression
in CeA, and to a lesser degree in LA and BLA (Nakagawa, et al., 2003). Fear
conditioning studies that utilize noxious foot-shock as an unconditional stimulus (US)
revealed that foot-shock administered within a context during training results in
increased CeA-Fos expression when compared to rats that did not receive foot-shock
within that same context (Milanovic, et al., 1998; Radulovic, Kammermeier, & Spiess,
1998). Deep somatic pain induced by formalin injection into the rat multifidus muscle
(i.e., low back muscle) produces significant Fos expression in the BLA (Ohtori, et al.,
2000).

The pharmacological activation of protein kinase C (PKC), via intrathecal

phorbol 12,13-dibutyrate administration, within the spinal dorsal horn produces
behavioral pain states (i.e., scratching, licking, biting, severe tail shaking, and
vocalizations), and these nociceptive behaviors correlate with Fos expression in the
cingulate cortex, parafascicular nucleus, and basolateral amygdala (Narita, et al., 2004).
That cellular activation of the amygdala arises from such a diverse typology of noxious
stimulation implicates the amygdala as a structure strongly involved in the experience of
pain.
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Excitotoxic lesions of CeA resulted in the abolition of conditioned place aversion
(CPA) supported by noxious chemical stimulation (i.p. administered acetic acid) or
formalin injection into the hind-paw, but failed to reduce associated nociceptive
behaviors (Tanimoto, Nakagawa, Yamauchi, Minami, & Satoh, 2003).

Acetic acid-

induced pain behaviors included typical writhing behavior (i.e., contraction of abdominal
muscles followed by extension of the hind limbs) and formalin-induced pain behaviors
included the elevation and the biting, licking, or shaking of the injected paw. These
results suggest a role of CeA in the generation of pain affect as measured by CPA, but
not pain sensation as measured by the aforementioned writhing and formalin-induced
pain behaviors. Because the forebrain does not integrate writhing behavior or formalin
behavior (Hammond, 1989; Matthies & Franklin, 1992), amygdalar lesions would not
affect these behaviors.

Additionally, electrolytic lesions of the CeA resulted in the

elevation of the threshold for tail-shock to elicit the vocalization after-discharge (VAD)
response (Borszcz & Leaton, 2003). Research in this laboratory validated VADs as a
model of pain affect (Borszcz, 1993, 1995a, 1995b; Borszcz, Johnson, & Fahey, 1994).
These vocalizations occur following a brief noxious tail-shock and are spectrographically
distinct from vocalizations that occur during tail-shock (VDS; Borszcz, 1995b, 2006).
This evidence that amygdala lesions suppress affective pain responses strongly
implicates the amygdala in the processing of the affective-motivational dimension of the
pain experience.
1.2 Nociceptive Processing within CeA: Contribution of Glutamate Receptors
As described earlier, the CeA receives nociceptive afferents via a variety of
pathways. In the rat, nociceptively responsive neurons in CeA are localized within the
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lateral capsular sub-division (CeALC). CeALC neurons have either wide dynamic range
(WDR) or nociceptive specific (NS) characteristics (Bird, et al., 2005; Han &
Neugebauer, 2005; Li & Neugebauer, 2004a, 2004b). WDR neurons respond to both
innocuous and noxious stimulation of the periphery with the rate of neural activity
related to intensity of stimulation, and NS neurons respond only to noxious stimulation.
Activation of both WDR and NS neurons occurs following stimulation of broad areas of
the body, indicating large receptive fields for both types of neuron (Bernard & Besson,
1990; Bernard, Huang, & Besson, 1992; Neugebauer & Li, 2002).
Nociceptive input to NS neurons in CeALC appears to be provided by the spinoparabrachio-amygdaloid pathway (Bernard & Besson, 1990; Ma & Peschanski, 1988).
Nociceptively responsive neurons in the external lateral pontine parabrachial (pPBel)
and external medial pontine parabrachial (pPBem) nuclei that project to CeALC are
innervated by projections from nociceptively responsive laminae I neurons of the spinal
dorsal horn (Todd, et al., 2002). These PB neurons lack WDR characteristics, and only
respond to noxious input from the periphery (i.e., possess NS characteristics; Bernard &
Besson, 1990).
Noxious-evoked activity in WDR neurons in CeALC is mediated by glutamate
receptors. Li and Neugebauer (2004a) recorded extracellular single-unit activity from
WDR neurons in CeALC in anesthetized rats. The neurons’ responses to graded brief
(15 s) mechanical stimuli (noxious pinch) applied to the knee were challenged by
administration of NMDA (APV) and non-NMDA (DNQX) receptor antagonists into the
CeA via reverse microdialysis. Both receptor antagonists suppressed noxious-evoked
neural activity in CeALC. APV failed to alter spontaneous background activity or the
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response of CeALC neurons to innocuous mechanical stimulation. Alternately, DNQX
also suppressed background activity and the response of CeALC neurons to innocuous
stimulation.
Given the contribution of the CeA to the production of affective behaviors in
response to threats, and the contribution of CeA-glutamate receptors to nociceptive
processing within the CeA, we evaluated the effects of CeA-administration of NMDA
and non-NMDA receptor antagonists on the generation of pain affect. We observed that
administration of APV (NMDA antagonist) or CNQX (non-NMDA antagonist) into the
CeA preferentially elevated the current intensity of tail-shock to elicit VADs (Spuz &
Borszcz, in preparation; see Figure 1 for APV data). The current intensity to elicit VDS
was elevated to a lesser degree; whereas, the current to elicit spinal motor reflexes
(SMRs = tail-flicks) was not altered by injection of glutamate receptor antagonists into
the CeA. These findings indicate that glutamate-mediated neuronal activation in CeA
contributes preferentially to the production of the affective response to pain.
1.3 Evidence for the Involvement of NMDA Receptors within the Amygdaloid Central
Nucleus in Antinociception
Whereas the aforementioned results indicate that NMDA (and non-NMDA) receptormediated neuronal excitation within CeA contributes to production of pain affect, a
variety of evidence indicates that activation of the CeA suppresses responses to
noxious stimulation.

Electrical stimulation of the CeA results in antinociception

measured as an increase in the tail-flick latency to noxious heating of the tail (Mena,
Mathur, & Nayar, 1995; Oliveira & Prado, 1998), a reduction of the tonic phase in the
formalin test and suppression of VDSs and VADs to noxious tail-shock (Mena, et al.,
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1995). Additionally, stimulation of the CeA suppresses shock-induced vocalizations in
guinea pigs (Leite-Panissi, Coimbra, & Menescal-de-Oliveira, 2003).
As systemic administration of NMDA agonists produces neuronal excitation within
CeA (Inada, Farrington, Moy, Koller, & Duncan, 2007; Radulovic, Blank, Nijholt,
Kammermeier, & Spiess, 2000) the possibility that NMDA receptor agonism within CeA
(like NMDA receptor antagonism) suppresses pain affect was evaluated. Preliminary
findings demonstrated that administration of NMDA into the CeA produced
antinociceptive effects similar to that observed following injection of APV into the CeA
(see Figure 2). That is, both treatments preferentially elevated VAD threshold. The
present study was designed to evaluate the mechanisms through which NMDA receptor
activation and antagonism within CeA produce suppression of pain affect.
Hypothesis
The central hypothesis of this study is that NMDA receptor antagonism within CeA
blocks nociceptive transmission to efferent sites of CeA that coordinate affective
responding to noxious stimulation; whereas, NMDA receptor activation within CeA
engages efferent projections of CeA that activate endogenous antinociceptive
mechanisms that suppress nociceptive transmission that contributes to production of
pain affect. Support for the former mechanism is provided by the aforementioned
findings that administration of an NMDA receptor antagonist into the CeA inhibits
noxious evoked neuronal activity within CeA (Li & Neugebauer, 2004a), and our finding
that administration of APV into the CeA suppresses pain-induced vocalizations The
latter mechanism is supported by reports that antinociception elicited by stimulation of
CeA is blocked by inactivation of the ventrolateral periaqueductal gray (vlPAG; Leite-
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Panissi, et al., 2003; Oliveira & Prado, 1998). The vlPAG is a core mesencephalic
structure that contributes to opiate-induced antinociception (Bodnar, Williams, Lee, &
Pasternak, 1988; Borszcz, 1995a; Borszcz, Johnson, & Thorp, 1996; Jensen & Yaksh,
1986), and is reciprocally interconnected with CeA (Mantyh, 1982, 1983a, 1983b).
Electrical stimulation of the CeA produces antinociception that is blocked by
pretreatment of the vlPAG with the mu-opioid receptor antagonist beta-funaltrexamine
(Oliveira & Prado, 2001). Moreover, glutamatergic stimulation of CeA activates
projection neurons in vlPAG through enkephalin-mediated disinhibition (Behbehani,
Jiang, & Chandler, 1990; da Costa Gomez & Behbehani, 1995; Sandkuhler, Willmann,
& Fu, 1989). Projections of these vlPAG neurons to limbic, thalamic and brainstem
sites contribute to the suppression of pain affect elicited by morphine injected into
vlPAG (Borszcz, 1995a, 1999).
Specific Aims
Based on preliminary findings, the specific aims of this study were as follows:
Aim #1: Complete the evaluation of the suppression of pain affect produced by
administration of NMDA into the CeA.


Anatomical specificity: It was hypothesized that administration of NMDA
into sites surrounding CeA will be less effective in suppressing VADs
compared to administration into the CeA.



Neurotoxicity: It was hypothesized that histological evaluation of CeA will
reveal that NMDA-mediated suppression of VADs is not related to NMDAinduced neurotoxicity.
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Aim #2: Evaluate the functional interaction between the CeA and vlPAG in the
suppression of pain affect.


It was hypothesized that if intra-CeA NMDA administration generates
antinociception through activation of enkephalinergic interneurons in
vlPAG, then suppression of VADs observed with intra-CeA NMDA
administration will be attenuated or abolished following the intra-vlPAG
administration of an enkephalin antagonist.

Aim #3: Evaluate the cellular response of the vlPAG to NMDA and NMDA
antagonist administered into the CeA.


It was hypothesized that if NMDA receptor antagonism blocks the throughput of nociceptive transmission at the level of the CeA, and if NMDA
receptor agonism activates neural projections involved in endogenous
antinociception, then the expression of the neural activity marker Fos
within the endogenous antinociceptive circuit will differ following intra-CeA
NMDA receptor antagonist vs. agonist.
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CHAPTER 2
Methods
2.1

General Methods

Animals
A total of ninety Long-Evans rats (Charles River, Raleigh, NC) ranging from 100-200
days old were used in these experiments. Pairs of rats were housed in plastic cages in
a climate-controlled vivarium (lights on 7 A.M. to 7 P.M.), and given ad libitum access to
food and water. Testing occurred during the light portion of the cycle. Rats were
handled two to three times over one week before surgery and before testing to minimize
the effects of stress from human contact.

All procedures were approved by the

Institutional Animal Care and Use Committee of Wayne State University.
Stereotaxic Surgery
All surgeries were performed under aseptic conditions. Rats were anesthetized with
sodium pentobarbital (50 mg/kg, i.p.) following pretreatment with atropine sulfate (1
mg/kg, i.p.). For implants aimed at CeA, ventral to CeA, and dorsal to CeA, two
stainless steel 26-gauge single-cannulae (Plastics One, Roanoke, VA) were
stereotaxically, bilaterally implanted above CeA according to coordinates extrapolated
from the rat brain atlas of Paxinos and Watson (Paxinos & Watson, 1998). The
coordinates (in mm) relative to the bregma suture and the top of the flat skull are as
follows: right implant (AP = -2.0, L = +4.0, DV= -6.0), left implant (AP = -2.0, L = +4.4,
DV= -6.0). For implants aimed lateral to CeA, two single 26-gauge cannulae were
bilaterally implanted above positions lateral to CeA using the following stereotaxic
coordinates (in mm): right implant (AP = -2.0, L = +5.2, DV = -6.0), left implant (AP =
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-2.0, L = +5.6, DV = -6.0). For implants aimed medial to CeA, two single 26-gauge
cannulae were bilaterally implanted above positions medial to CeA using the following
stereotaxic coordinates (in mm): right implant (AP = -2.0, L = +2.8, DV = -6.0), left
implant (AP = -2.0, L = +3.2, DV = -6.0).
For implants aimed toward the vlPAG, one stainless steel 26-gauge singlecannula (Plastics One, Roanoke, VA) was implanted unilaterally above the vlPAG at a
twenty-degree angle according to coordinates extrapolated from the rat brain atlas of
Paxinos and Watson (Paxinos & Watson, 1998). Rats received vlPAG implants on
either the left or right side based upon random assignment. The coordinates (in mm)
relative to the bregma suture and the top of the flat skull were as follows: AP = -7.8, L =
+2.6, DV= -3.6.
All cannulae were affixed to the skull with four stainless steel bone screws (3/16 in)
and cranioplastic cement. Each guide cannula was fitted with a 33-gauge dummy
cannula that extends the length of the guide to maintain its patency. Rats were given 710 days to recover before the initiation of testing.
Drug Injections
Intracerebral CeA injections were administered in a constant volume 0.25μl via 33guage injectors. Injectors targeted at CeA extended 3mm beyond the end of the
cannula. Injectors targeted at sites dorsal to CeA extended 1.8mm beyond the end of
the cannula, and injectors targeted at sites ventral to CeA extended 4.2mm beyond the
end of the cannula. Intracerebral vlPAG injections were administered in a constant
volume 0.5μl via a 33-guage injector. Injectors targeted at vlPAG extended 3mm
beyond the end of the cannula. All injections were made at a constant rate over 1 min
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via an infusion pump (Harvard Model PHD 2000) and injectors were left in place for 2
min after the completion of injections to aid the diffusion of drugs into tissue. N-methylD-aspartate (NMDA; Tocris, Ellisville, MO), D-(-)-2-Amino-5-phosphopentanoic acid
(APV; Tocris, Ellisville, MO), and H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP;
Sigma-Aldrich, St. Louis, MO) were dissolved in normal sterile saline.
Histological Analysis
All rats with the exception of those that underwent Fos expression analysis were
sacrificed by carbon dioxide asphyxiation at the completion of their testing sequence.
Injection sites were marked by safrin-O dye (0.25µl) and brains were extracted and
placed in a 20% (w/v) sucrose formalin solution for 48-72 hours. Brains were sectioned
at 45µm on a freezing microtome, and injection sites were localized with the aid of the
Paxinos and Watson (1998) brain atlas by a researcher unaware of the results from
behavioral testing.
Rats from the NMDA dose response study that received the highest NMDA dose
(1µg/.25µl per side) were stained using cresyl violet in order to assess the potential
neurotoxic effects of NMDA qualitatively. Stained tissue was histologically examined at
10X magnification and compared to stained tissue from rats that received saline
injections.

Neuronal cell loss or proliferation of glial cells surrounding the NMDA

injection site was considered evidence for neurotoxic damage.
2.2 Experimental Design
Dose Response Analysis
To quantify a dose-response relationship between CeA-administered NMDA agonist
and SMR, VDS, and VAD thresholds, rats received bilateral injections of one dose of
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NMDA (0.1μg, 0.25μg, 0.5μg, and 1μg/side) and saline into the CeA prior to two
separate test sessions.

Injections of drug were given over 2 min, and the injector

remained in place for 1 min to aid in the diffusion of drug into tissue. Doses of NMDA
were determined by preliminary results. Saline injections were maintained as the first
test in order to ascertain baseline levels of responding. Test sessions were separated
by 4 – 6 days, each drug group contained 6 or 7 rats, and the saline group contained 21
rats (summation of saline treatments from all rats in all drug treatment groups).
Anatomical Specificity
The anatomical specificity of NMDA mediated antinociception within the CeA was
evaluated by administration of NMDA (1μg/side) into sites surrounding the CeA. Rats (n
= 7) received a saline test followed by a test with NMDA agonist on separate test
sessions at each of three separate anatomical sites by means of injectors that extend
1.8mm, 3.0mm, and 4.2mm beyond the length of the guide cannulae (see Figure 3 for a
schematic of injector placement). Test sessions were separated by 5 – 7 days. NMDA
administration within the CeA in this study permitted the replication of NMDA (1μg/side)
on response thresholds, and these data were used to compare the effects of NMDA
administered into sites surrounding the CeA.
CeA NMDA – vlPAG CTAP Interaction
Rats (n = 8) first received three testing sessions (sessions separated by 5 – 7 days)
with different pairs of injections separated by 15 min in the following order: CeA saline +
vlPAG saline; CeA saline + vlPAG CTAP (0.25µg/0.5µl); CeA NMDA (0.025µg/0.25µl
per side) + vlPAG saline.

These tests allowed for the assessment of baseline
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responding, CTAP effects on baseline responding, and the replication of NMDA-induced
antinociception, respectively.
The capacity for vlPAG mu-opiate receptors to mediate CeA-NMDA induced
antinociception was evaluated by a final test using the following pair of injections: CeA
NMDA + vlPAG CTAP.
The dose of NMDA was determined following preliminary experimentation to
determine the dose of NMDA that consistently produced elevations in threshold that
were below ceiling. This permitted the measurable capacity for CTAP to attenuate the
effects of NMDA.

The dose of CTAP used was determined following preliminary

experiments.
2.3 Pain Testing
Testing Apparatus
Rats were placed into custom made Velcro body suits and restrained on a Plexiglas
pedestal using Velcro strapping that passes through loops located on the underside of
the suits. This design maintained the rat in a crouched posture throughout testing and
permitted unobstructed access to the head for intracerebral injections. Testing was
conducted within a sound attenuating, lighted, and ventilated chamber equipped with a
small window that enabled visual monitoring of the animal during testing.
Tail-shock

(20ms pulses at 25Hz for 1,000ms) was delivered by a computer

controlled constant current shocker (STIMTEK, Arlington, MA) through electrodes
(0-gauge stainless steel insect pins) placed intracutaneously on opposite sides of the
tail, 7.0cm (cathode) and 8.5cm (anode) from the base. The utility of this form of tail-
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shock as a noxious stimulus has been extensively discussed (Borszcz, 1993, 1995b;
Borszcz, et al., 1994; Bromm & Meier, 1984).
Spinal motor reflexes (SMRs) were measured with a semi-isotonic displacement
transducer (Lafayette Instruments Model 76614, Lafayette, IN) attached to the rat’s tail
with cotton thread. The output voltage of the transducer was amplified (x50) and then
digitized (500Hz sampling rate) by an analog-to-digital converter of the microcomputer.
SMR was defined as movement of the transducer arm by at least 1mm following shock
onset.
Vocalizations were recorded by a pressure-zone microphone (Realistic model
33-1090, Tandy, Ft. Worth, TX) located on the wall of the testing chamber 15cm from
the rat’s head. The microphone was connected to an audio amplifier (Technics model
SA-160, Tandy, Ft. Worth, TX) and a 10-band frequency equalizer adjusted to
selectively amplify frequencies above 1500Hz.

The filtering of low frequencies

prevented extraneous noise (i.e., rats’ respiration and movement artifacts) from
contaminating vocalization records. The output of the amplifier was integrated by a
Coulbourn Instruments (Allentown, PA) contour following integrator (2ms time base) and
digitized (500Hz sampling rate) by a separate analog-to-digital converter of the
microcomputer.
Performance Measurement
Performance variables for each animal were recorded by the microcomputer during
every test. SMR performance consists of the latency (ms), peak amplitude (mm), and
magnitude (cm x ms) of tail movement on each trial. Vocalization performance includes
the peak intensity (in decibels: SPL, B scale), latency (ms), and duration (ms) of
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vocalizations during the shock epoch (VDS = vocalization during shock) and for the
2,000 ms interval following shock termination (VAD = vocalization afterdischarges).
Previous studies revealed that changes in these performance variables reflect the
confounding influence of motor impairments on increases in response thresholds
(Borszcz, 1993; Borszcz, et al., 1994).
Testing Protocol
For two consecutive days prior to testing, rats were be adapted to the testing
apparatus for a period of 20 min each day to minimize the effects of restraint. For all
studies, testing began 6-10 min following completion of intra-CeA injections.

Test

sessions consisted of 20 randomly presented trials. On 16 trials, tail-shocks between
0.02 mA and 2.50 mA were delivered, and on four trials no current was delivered so as
to assess false alarm rates. Trials were presented with a minimum intertrial interval of
30 sec and each test session concluded within 20 min. These procedures cause no
observable damage to the tail. Following each test session, the testing apparatus was
cleaned with 5% ammonia hydroxide to eliminate stress odors (Fanselow, 1985).
Data Analysis
Threshold data was reorganized in ascending order according to tail-shock intensity.
SMR, VDS, and VAD thresholds for each rat were calculated as the minimum current
intensity from a string of at least two consecutive intensities that generated the
response. All analyses used alpha = .05.
Response thresholds for the NMDA dose response experiment were directly
compared using repeated-measures MANOVA. A significant omnibus MANOVA was
followed by within-subjects contrasts of response thresholds. The effects of dose on
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individual responses were analyzed by one-way ANOVA. The doses of NMDA that
elevated response thresholds above baseline levels (i.e., saline thresholds) were
determined by comparing thresholds following saline and NMDA treatments using
Dunnett’s test.

The capacity of NMDA to elevate response thresholds following its

injection into sites surrounding the CeA was analyzed for each response by one-way
ANOVA.

Post-hoc comparisons using independent samples t-tests were used to

assess response thresholds generated following the administration of NMDA (1µg/.25µl
per side) or saline into the CeA and into sites surrounding the CeA. The capacity of
vlPAG-CTAP to reduce NMDA-CeA induced elevations of response thresholds was
analyzed across treatment groups for each response by a one-way ANOVA followed by
post-hoc independent samples t-test.
Testing sessions that included a threshold greater than 2.0 standard deviations from
the mean threshold was considered an extreme outlier and was excluded from analysis
(n = 2). Rats with incorrectly placed cannulae were also excluded from analysis (n = 2).
Rats were also excluded from analysis due to death during surgery (n = 1), illness
(n = 2) or complications related to their surgical cannulae implants (n = 3).
2.4 Immunohistochemistry
Experimental Design - CONTEXT
Male Long Evans rats were first randomly assigned to one of three context groups:
Home Cage, Chamber Only, and Shock. Home Cage rats resided in the laboratory
holding room for three consecutive days (at least 3h/day). Chamber Only rats were
exposed to the afore-described tail-shock vocalization response test chamber, but did
not receive shock, for three consecutive days (20 min/day) in addition to residing in the
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laboratory holding room. Shock rats followed protocol identical to the Chamber Only
group except that on Day 3 a tail-shock vocalization-response test (see above) was
given to the rat in the chamber.
Rats within each Context group were further randomly assigned to one of three drug
treatment groups: saline, APV, or NMDA. Rats were given intra-CeA treatments
bilaterally. The doses used in these groups were as follows: saline (0.25µl/side), APV
(4µg in 0.25µl/side), and NMDA (1µg in 0.25µl/side).
Free-Floating Immunohistochemistry Protocol
Two hours after the intracerebral injection, the animals were deeply anaesthetized
with an overdose of sodium pentobarbital into the liver (120 mg/kg) and transcardially
perfused with 0.1M phosphate-buffered saline (pH = 7.4) followed by 4%
paraformaldehyde (PFA) in 0.1M PBS (pH 7.4; 4° C). The brains were removed and
post-fixed at 4° C for 1.5 hours in 4% PFA and then stored for at least 48 hours in 30%
sucrose in 0.1M PBS at 4° C for cryoprotection or in long-term cryoprotectant (0.1M
PBS + ethylene glycol + sucrose) at -20° C. Brains were sliced transversely at 45µm
and vlPAG sections with the AP coordinates -7.64 through -8.72 mm posterior to
Bregma were collected.
Tissue sections were collected in 0.1M PBS and subsequently processed freefloating according to the avidin–biotin-peroxidase complex (ABC) method. Primary
antibody concentrations were determined (1:5000) following a titration protocol that
varied the concentration of primary while leaving the secondary at a constant (1:200 per
manufacturer). All reactions were carried out under agitation at room temperature.
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On the first day, the sections were washed six times (10 min each) in 0.1M PBS and
then incubated with 0.3% H2O2 for 30 min. Sections were then washed three times with
0.1M PBS (5 min each) and then incubated with blocking buffer (0.3% Triton X-100, 1%
normal goat serum, 1% bovine serum albumin in 0.01M PBS, pH = 7.4) for 60 min to
reduce non-specific antibody staining. Sections were then incubated overnight with the
primary Fos rabbit polyclonal IgG (Santa Cruz, USA) at a concentration of 1:5000 in
blocking buffer.
On the second day, sections were washed three times (10 min each) with PBST
(0.1M PBS with 0.02% Triton X-100) and then incubated for 2 hr with secondary
biotinylated goat anti-rabbit IgG (H+L) (Vector Laboratories) at a concentration of 1:200
in blocking buffer. The sections were then incubated for 1 hr with the avidin and biotin
complex (A and B solution of the ABC kit, Vector Laboratories) at a concentration of
1:500 in PBST, and then again washed three times in PBST (5 min per wash) followed
by two washes in 0.05M Tris-HCl (pH = 7.6; 5 min each). Finally, chromagen was
visualized with 0.005% 3,3’V-diaminobenzidine (Sigma), 0.6% nickel ammonium sulfate,
and 0.005% H2O2 in 0.05M Tris-HCl. Tissue sections were washed twice with 0.05 M
Tris-HCl (5 min each) and then washed in distilled water for 10 min.
Quantification of Fos-Positive Cells
Tissue sections were mounted on gelatin-coated slides, dehydrated, coverslipped,
and photographed at with a Nikon Eclipse 80i microscope with a digital camera attached
to it (Cool Snap Photometrics EZ). The vlPAG was photographed at 40x and compared
to the rat brain atlas (Paxinos & Watson, 1998) as an orientation aid for tracing the
vlPAG. Images were magnified to 200x, and a 400µm x 300µm box was placed within
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the confines of the vlPAG. Fos immunoreactivity was visualized as a dark reaction
product inside neuronal nuclei. The number of Fos-positive nuclei was counted in the
box by hand with the aid of a computerized cell counting system (Nikon Elements
Software, 3.1). The vlPAG was bilaterally counted in each rat and counted on three to
four separate sections collected from each rat.

The results are expressed as the

number of Fos-positive nuclei.
Data Analysis
The number of Fos-positive nuclei is expressed as mean ± S.E.M. Results were
analyzed using a two-way between-subjects ANOVA with drug treatment (saline, APV,
NMDA) and context (Home Cage, Chamber, Shock Test) as between-group factors
followed by one-way ANOVAs with Dunnett’s post-hoc tests. The alpha level was .05
for all analyses.
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CHAPTER 3
RESULTS
3.1 NMDA Dose Response Analysis
The effects of the bilateral administration of NMDA into the CeA on SMR, VDS,
and VAD thresholds are depicted in Figure 2, and the distribution of the bilateral
administration sites are depicted as black triangles in Figure 4. The repeated-measures
MANOVA (Wilk’s λ) comparison of response thresholds revealed significant main
effects of response (F(2,41) = 122.06, p < 0.001) and dose (F(4,42) = 21.94, p < 0.001),
and a significant Response x Dose interaction, (F(8,82) = 11.30, p < 0.001). One-way
ANOVA revealed that VDS and VAD thresholds were elevated in a dose-dependent
manner by NMDA administration [VDS: F(4,46) = 9.75, p < 0.001; VAD: F(4,46) = 32.28,
p < 0.001], but NMDA treatments did not affect SMR thresholds, F(4,46) = 2.44, p >
0.05.

Post-hoc analysis using Dunnett’s test revealed that 0.25µg NMDA was the

minimum dose required to significantly elevate VDS thresholds (M = 1.00, SEM = .31)
above those observed with saline treatment (M = .06, SEM = .01).

Dunnett’s test

revealed that 0.1µg NMDA was the minimum dose required to significantly raise VAD
thresholds (M = .66, SEM = .14) above those observed with saline treatment (M = .10,
SEM = .01).

Dunnett’s test revealed that bilateral 0.1µg NMDA administration

preferentially elevated the VAD response over the VDS response, (VAD: M = .66, SEM
= .14; VDS: M = .22, SEM = .05, respectively).
3.2 NMDA Anatomical Specificity
Bilateral administration of saline into the CeA and sites surrounding CeA did not
produce a significant difference in response thresholds, t(17) = 0.20, p > .05; thus, these
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data were combined. The effects of bilateral administration of saline and 1µg NMDA
into the CeA and sites surrounding CeA are depicted in Figure 5.
One-way ANOVAs revealed that vocalization thresholds differed with respect to
treatment location (Fs(2,37) > 24.76, p < .05), but SMRs did not differ (F(2,37) = .88, p >
.05). Independent samples t-tests revealed that 1µg NMDA administration into the CeA
significantly elevated VDS and VAD thresholds above those observed with saline
administration (ts(28) > 6.29, p < .05). Independent samples t-tests further revealed
that 1µg NMDA administration into sites surrounding the CeA produced significantly
weaker elevations on VDS and VAD thresholds compared to the administration of 1µg
NMDA into the CeA (ts(17) > 3.27, p < .05). Figure 4 depicts administration sites where
NMDA effectively elevated (black squares, NMDA-CeA) or failed to elevate (black
circles, NMDA-other) VAD thresholds.
3.3 Neurotoxicity Analysis
Cresyl violet stained CeA sections from rats that received bilateral microinjections of
1µg NMDA did not produce any pattern of neuronal cell loss or proliferation of glial cells.
See Figure 11 for representative sections from an animal treated with bilateral CeAsaline and bilateral CeA-1µg NMDA. As depicted, there is no evidence of neurotoxicity
within the NMDA CeA section compared to the saline treated section.
3.4 CeA NMDA – vlPAG CTAP Interaction
The effects of the bilateral administration of 0.025µg NMDA into the CeA challenged
by the unilateral administration of 0.25µg CTAP into the vlPAG on SMR, VDS, and VAD
thresholds are depicted in Figure 6, and the distribution of the administration sites are
depicted as black circles in Figure 7.
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One-way ANOVA revealed a significant interaction between CeA treatment and
vlPAG treatment for SMR and VAD thresholds (Fs(1,32) > 6.00, ps < .05), but not VDS
threshold (F(1,32) = 2.64, p < .05). Two points can explain the SMR interaction. First,
the variability of the NMDA-CeA + CTAP-vlPAG group is extremely small. Second,
mean data suggests that sal-CeA + CTAP-vlPAG treatment tends to elevate SMR
threshold, but NMDA-CeA + CTAP-vlPAG treatment tends to lower SMR threshold.
Independent samples t-test (one-tail) revealed that, as expected given the doseresponse analysis, NMDA-CeA + sal-vlPAG treatment resulted in a significant elevation
of VAD threshold above that observed with sal-CeA + sal-vlPAG treatment (t(14) = 2.29,
p < .05). Independent samples t-test (one-tail) revealed that, as hypothesized, NMDACeA + CTAP-vlPAG treatment significantly attenuated VAD threshold compared to
NMDA-CeA + sal-vlPAG treatment (t(14) = 1.87, p < .05).
3.5 Fos Expression within vlPAG
The effects of bilateral intra-CeA treatment and context on the number of Fospositive nuclei within the vlPAG are depicted in Figure 8. Representative sections with
Fos expression are shown in Figure 9. The two-way ANOVA (treatment x context)
revealed a significant main effect of treatment on the number of Fos-positive nuclei
within the vlPAG (F(2,36) = 59.86, p < .05) and a significant treatment x context
interaction (F(4,36) = 3.53, p < .05), but did not reveal a main effect of context (F(2,36)
= .03, p > .05). One-way ANOVA revealed significant simple effects within the Home
Cage, Chamber Only, and Shock contexts (Fs(2,11) > 4.46, ps < .05).

Post-hoc

analysis via Dunnett’s revealed that within the Home Cage context, the number of intravlPAG Fos-positive nuclei was greater in animals that received bilateral intra-CeA 1μg
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NMDA (M = 29.22 ± SEM = 4.23) compared to animals that received intra-CeA saline
(M = 5.58 ± SEM = 0.89) and intra-CeA 4μg APV (M = 7.78 ± SEM = 0.85). Within the
Chamber Only context, the number of intra-vlPAG Fos-positive nuclei was greater in
animals that received bilateral intra-CeA 1μg NMDA (M = 21.07 ± SEM = 3.63)
compared to animals that received intra-CeA 4μg APV (M = 8.73 ± SEM = 0.82). Within
the Shock Test context, the number of intra-vlPAG Fos-positive nuclei was greater in
animals that received bilateral intra-CeA 1μg NMDA (M = 32.05 ± SEM = 3.32)
compared to animals that received intra-CeA saline (M = 4.35 ± SEM = 0.90) and intraCeA 4μg APV (M = 5.67 ± SEM = 1.29).
One-way ANOVA revealed that SMR, VDS, and VAD thresholds in the Shock
Test Context differed with respect to CeA treatment (Fs(2,61) > 5.24, ps < .05).
Independent samples t-tests revealed that compared to saline, SMR, VDS and VAD
thresholds were elevated to a greater extent following 4µg APV (ts(45) > 2.73, ps < .05)
and 1µg NMDA (ts(48) > 3.01, ps < .05). SMR and VAD threshold were not significantly
different between 4µg APV and 1µg NMDA (ts25) < 1.83, ps > .05), but VDS threshold
was significant (t(25) = 2.28, p <.05).
Figure 10 depicts mean threshold data for saline, APV, and NMDA from animals
in the Fos, APV dose response, NMDA dose response, and CeA-vlPAG Interaction
studies. Independent samples t-tests (one-tailed) revealed that compared to intra-CeA
saline treatment, bilateral intra-CeA APV (t(45) = 7.86, p < .05) and NMDA (t(48) =
14.08, p < .05) significantly elevated VAD thresholds. Threshold elevations following
APV treatment did not significantly differ from those following NMDA treatment (t(25) =
1.83, p < .05).
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3.6 Performance Analysis
3.6.1 Response Profiles
Of the four experiments that composed this study, 388 test trials were sham trials
(i.e., no shock given). False alarm rates were low (SMR = 1.80%, VDS = 0.00%, VAD =
0.00%) and indicate that behaviors did not occur spontaneously or as a result of drug
treatment, but instead were generated via tail-shock.

SMR, VDS, and VAD reflect

nociceptive processing at progressively higher levels of the neuraxis. Analysis of rats
that received transections of the neuraxis revealed that SMR responses are organized
at the spinal level, VDS within the medulla below the pontomedullary border, and VAD
within the forebrain (Borszcz, Johnson, Anderson, & Young, 1992; Carroll & Lim, 1960).
On the remaining 1,552 trials where tail-shocks were administered, responses
organized rostrally within the CNS were rarely generated without those integrated more
caudally within the CNS. VAD generation, without concomitant elicitation of VDS and
SMR, occurred on 0.58% of all trials. VDSs were elicited without SMR on 0.32% of the
trials in which VDS was the most rostrally elicited response.
3.6.2 Response Characteristics
SMR

reaction

time

(SMR.RT),

amplitude

(SMR.AMP),

and

magnitude

(SMR.MAG); VDS reaction time (VDS.RT), amplitude (VDS.AMP), and duration
(VDS.DUR); and VAD reaction time (VAD.RT), amplitude (VAD.AMP) and duration
(VAD.DUR) were recorded at threshold for vehicle and each drug treatment condition
(see Table 1, mean ± standard error of the mean), and compared to saline treatment
threshold (i.e., baseline) using a one-way ANOVA with Dunnett’s post-hoc tests (see
Table 2).
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NMDA Dose Response and Anatomical Control Studies
Comparison of SMR performance variables across saline and NMDA drug
treatments revealed that SMR performance at threshold was not affected by NMDA
treatments, Fs(4,83) < 0.81, ps > .05.

Comparison of VAD performance variables

across saline and NMDA drug treatments revealed that VAD performance at threshold
was not affected by NMDA treatments, Fs(4,74) < 2.26, ps > .05. Comparisons of VDS
performance variables demonstrated that reaction time of VDSs at threshold were not
altered by NMDA treatment (F(4,79) = 1.21, p > .05), but the amplitude and duration of
VDSs were significantly lower following NMDA treatments, Fs(4,79) > 3.18, ps < .05.
Post-hoc analysis revealed that the amplitude of VDS was decreased compared to
baseline following bilateral administration of 1µg NMDA.

Post-hoc analysis revealed

that the duration of VDS was decreased compared to baseline following bilateral
administration of 0.25µg NMDA, 0.5µg NMDA and 1µg NMDA. The effect on VDS
amplitude is small (M1µg NMDA = 85.52 ± SEM = 1.22 vs. Msaline = 90.06 ± SEM = 0.94)
and did not occur in other experiments. The effects on VDS duration also did not occur
in the 1µg NMDA group in the Fos Expression Study – Shock Group.
CeA – vlPAG Interaction Study
Comparison of SMR, VDS, and VAD performance variables across baseline
(saline CeA + saline vlPAG) and drug treatments revealed that all response
characteristics were not significantly affected by treatment, Fs(3,30) < 1.40, ps > .05.
Fos Expression Study – Shock Group
Comparison of performance variables across bilateral intra-CeA saline, 4µg APV,
and 1µg NMDA revealed that all response characteristics were not significantly affected
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by treatment (SMR: Fs(2,11) < 1.54, ps > .05; VDS: Fs(2,8) < 2.38, ps > .05; VAD:
Fs(1,6) < 2.32, ps > .05). Three animals in the 1µg NMDA group did not respond to any
shock intensity with a VDS, and thus only one animal’s threshold data is reported for
VDS.RT, VDS.AMP, and VDS.DUR. Likewise, all four animals in the 1µg NMDA group
did not respond to any shock intensity with a VAD, and thus no threshold data could be
reported for VAD.RT, VAD.AMP, and VAD.DUR.
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CHAPTER 4
DISCUSSION
The present study provides the first demonstration of behavioral antinociception
generated by administration of an NMDA receptor agonist into the CeA. Administration
of NMDA into the CeA produced dose-dependent increases in VAD and VDS thresholds
but failed to elevate SMR threshold.

Direct comparisons of response thresholds

revealed that VAD threshold was preferentially elevated compared to VDS threshold by
the intra-CeA injection of NMDA, and the minimum effective dose of NMDA to elevate
VAD threshold was lower than the dose that raised VDS threshold. The increases in
VAD threshold cannot be attributed to drug-induced motor deficits as increases in VAD
threshold were not accompanied by performance decrements.

Increases in VDS

threshold may reflect the effects of drugs on performance. NMDA produced decreases
in VDS duration at threshold and increases in VDS latency at threshold. Decrements in
these performance variables following systemic drug treatments (i.e., morphine,
diazepam) were shown to elevate response thresholds independent of the drugs’ effect
on sensory processing (Borszcz, et al., 1994).

However, these decrements were

relatively small and were not observed in the CeA-NMDA + vlPAG-CTAP interaction
study.
Similar to the present results, administration of carbachol, serotonin (5-HT), the
5-HT1A/7 agonist 8-hydroxy-dipropylaminotetralin (8-OH-DPAT), or morphine into either
the basolateral amygdala (BLA), thalamic parafascicular nucleus (nPF), or ventral
tegmental area (VTA) produced selective increases in VAD and VDS thresholds without
an accompanying increase in SMR threshold (Harte, Hoot, & Borszcz, 2004; Harte,
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Kender, & Borszcz, 2005; Harte, Lagman, & Borszcz, 2000; Kender, Harte, Munn, &
Borszcz, 2008; Nandigama & Borszcz, 2003). The failure to observe increases in SMR
threshold does not reflect the resistance of this response to antinociceptive treatments.
In previous studies, administration of morphine into the rostral ventromedial medulla
(RVM) or vlPAG produced significant increases in SMR, VDS, and VAD thresholds
(Borszcz, 1995a; Borszcz, Johnson, & Thorp, 1996; Borszcz & Streltsov, 2000), and the
intrathecal administration of morphine, 5-HT, or norepinephrine was equally effective in
raising SMR, VDS, and VAD thresholds (Borszcz, Johnson, & Williams, 1996). The
capacity of these central treatments to elevate SMR threshold also demonstrates that
SMRs are not generated by direct stimulation of the tail musculature by the tail-shock.
These findings indicate that the capacity to elevate SMR threshold depends on the site
within the CNS at which antinociceptive treatments are administered.
The capacity of CeA-administered NMDA to elevate vocalization thresholds is
likely limited to its action within CeA. Bilateral administration of the highest dose of
NMDA (1µg/side) into sites surrounding the CeA produced greatly attenuated increases
in VAD and VDS thresholds. Thus, it is unlikely that the effects of NMDA observed in
the dose response study are the result of drug spread into these surrounding sites.
Further, the effect of NMDA on vocalization thresholds cannot be the result of an
excitotoxic lesion. NMDA is a known neurotoxin at high doses, but the doses used in
the present study are well below those shown to produce cell loss (8 µg; Maisonnette,
Kawasaki, Coimbra, & Brandao, 1996).

Further, qualitative analysis of cresyl-violet

stained tissue revealed that bilateral treatment with 1µg NMDA failed to produce cell
loss. Additional evidence against elevations of vocalization thresholds being the result
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of a lesion comes from the results of the CeA-NMDA + vlPAG-CTAP study, as CeANMDA induced vocalization threshold elevations were attenuated via vlPAG-CTAP
administration. If the threshold elevations were due to a lesion of CeA, CTAP would be
unable to reverse these elevations. This result also argues against the observed effects
on vocalization thresholds being the consequence of NMDA induced elliptic-type neural
activity producing a functional lesion in CeA (Frenk & Yitzhaky, 1981). Therefore, the
capacity of NMDA administered into the CeA to suppress pain-induced vocalizations is
the result of activation of NMDA receptors within CeA.
The preferential increase in VAD threshold after intra-CeA APV or NMDA
administration reflects suppression of the affective reaction to noxious stimulation.
Previous research in this laboratory validated VADs as a rodent model of pain affect.
VADs have distinct spectrographic characteristics compared to VDSs (Borszcz, 1995b,
2006; Borszcz & Leaton, 2003), and are preferentially suppressed by systemically
administered drug treatments that preferentially suppress the affective response of
humans to pain (Borszcz, et al., 1994; Gracely, et al., 1978; Price, von der Gruen,
Miller, Rafii, & Price, 1985). Generation of VADs is also suppressed by damage of or
drug treatments into forebrain sites known to contribute to production of the affective
response of humans to clinical and experimental pain (Borszcz, 1999; Borszcz &
Leaton, 2003; Greer, 2007; Harte, et al., 2005; Harte, et al., 2000; Hoffmeister, 1968;
Mark, Ervin, & Yakovlev, 1961; Nandigama & Borszcz, 2003; Sweet, 1980; Zubieta, et
al., 2001). Additionally, the capacity of noxious tail-shock to support fear conditioning is
directly related to its production of VADs (Borszcz, 1993, 1995b; Borszcz & Leaton,
2003), and fear conditioning supported by electrical stimulation of the ventromedial
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hypothalamus is correlated with generation of VAD-like vocalizations (i.e., vocalizations
with the same spectrographic characteristics as VADs; (Borszcz, 2006).
It is of interest that both the NMDA receptor antagonist APV (Spuz & Borszcz, in
preparation) and the agonist NMDA produce similar behavioral effects when
administered within the CeA. NMDA receptors have been identified in the medial (CeM)
and capsular (CeC) subnuclei of the CeA in rat (Farb, Aoki, & Ledoux, 1995; Gracy &
Pickel, 1995). It is proposed that manipulation of NMDA receptors within CeA produces
affective analgesia, measured as elevations in VAD thresholds, via the action of APV
and NMDA at separate neural populations within CeC and CeM, respectively.
4.1 Model of Intra-CeA APV-Induced Affective Analgesia
The CeA receives nociceptive-specific information from the spinal cord dorsal
horn via the indirect spino-parabrachio-amygdaloid (Bernard & Besson, 1990; Ma &
Peschanski, 1988; Todd, et al., 2002) pathway and the direct spino-amygdaloid
pathway (Burstein & Potrebic, 1993; Cliffer, Burstein, & Giesler, 1991; Newman, et al.,
1996).

Electrophysiology studies indicate that the lateral region of CeC (CeALC)

contains the greatest proportion of neurons activated by noxious peripheral stimulation
of the rat body (Bernard, et al., 1992).

Stimulation of these CeALC neurons

antidromically activates pontine parabrachial (PB) neurons that respond exclusively to
noxious cutaneous stimulation (Bernard & Besson, 1990). In-vitro whole-cell voltageclamp recordings of rat CeALC neurons revealed that following PB electrical stimulation,
CeALC neurons exhibit monosynaptic excitatory post-synaptic currents (EPSCs; Bird, et
al., 2005).

Bath application of APV to the slices does not alter evoked EPSCs,

suggesting that glutamatergic pain transmission via the PB-CeALC pathway does not
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interact with CeALC-NMDA receptors.

However, in vivo investigations showed that

administration of APV into the CeALC of rats does attenuate noxious, but not
innocuous, evoked neural activity in the CeALC (Li & Neugebauer, 2004a).

Thus,

NMDA dependent nociceptive neural transmission interacting with the CeALC must
project from regions other than the PB. An alternative pathway for NMDA dependent
glutamate neurotransmission to interact with CeA is via the direct spino-amygdaloid
pathway. To the best of our knowledge, no study has investigated whether glutamate is
the major neurotransmitter involved in this direct spinoamygdaloid projection. Also as
described earlier, the CeA receives nociceptive input relayed from the spinal dorsal horn
via the intralaminar thalamus, yet no study has investigated the neurochemistry
underlying these thalamic afferents or their contribution to noxious-evoked activity in the
CeA.
Our previous demonstration that intra-CeA administration of APV produces dosedependent increases in vocalization thresholds, with a preferential influence on VAD
thresholds (Siegel, 2005; Spuz & Borszcz, in preparation) likely reflects the suppression
of nociceptive processing at the level of the CeALC NMDA receptors. This blockade
inhibits the further transmission of nociception to efferent sites of the CeA that
coordinate affective responding to noxious stimulation. As noted earlier, CeA is the
major output nucleus of the amygdaloid complex, and its projections to the ventromedial
hypothalamus (VMH) and dorsolateral PAG (dlPAG) govern the execution of innate
affective reactions to environmental threats, including pain (Borszcz & Spuz, 2009).
The dorsomedial division of the VMH (dmVMH) and dlPAG are the core mesolimbic
structures that control execution of affective responses to environmental threats (Siegel,
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2005). Both the dmVMH and dlPAG exhibit Fos activation following exposure to either
noxious or non-noxious threatening stimuli (Beckett, Duxon, Aspley, & Marsden, 1997a;
Bullitt, 1990; Canteras, Chiavegatto, Ribeiro do Valle, & Swanson, 1997; Dielenberg,
Hunt, & McGregor, 2001; Liu, Qiang, & Qiao, 1998; Parry, Semenenko, Conley, &
Lumb, 2002; Rodella, Rezzani, Gioia, Tredici, & Bianchi, 1998; Sandner, et al., 1993),
and inactivation or damage of these sites block naturally occurring affective responses
to threats (Canteras, et al., 1997; Cheu & Siegel, 1998; Markham, Blanchard, Canteras,
Cuyno, & Blanchard, 2004).

Stimulation of the dmVMH and dlPAG elicits affective

responses in rats, cats and monkeys (Fernandez De Molina & Hunsperger, 1962; Lipp
& Hunsperger, 1978; Milani & Graeff, 1987), and in humans generates reports of fear,
anxiety, and horror (Ervin, Mark, & Stevens, 1969; Heath, 1975; Iacono & Nashold,
1982; Tasker, 1982). For all these species, vocalizations are part of their affective
reaction to imminent threat and are produced as part of their affective reaction to
dmVMH or dlPAG stimulation (Blanchard, Hynd, Minke, Minemoto, & Blanchard, 2001;
Blanchard, Flannelly, & Blanchard, 1986; Fernandez De Molina & Hunsperger, 1962;
Jurgens & Pratt, 1979).
Previous research in this laboratory (Borszcz, 2006) demonstrated that electrical
or chemical stimulation of dmVMH generates VAD-like vocalizations. Manipulation of
GABAA neurochemistry within the dmVMH altered the threshold for elicitation of VADs
by dmVMH electrical stimulation or tail-shock. Administration of the GABAA antagonist
bicuculline or the GABAA agonist muscimol into the dmVMH lowered and elevated VAD
threshold, respectively. These treatments did not alter thresholds of VDS or SMR
elicited by tail-shock. Bicuculline and muscimol administered into the dmVMH also
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elevated and lowered the asymptotic level of fear conditioning supported by dmVMH
stimulation or tail-shock.
The dlPAG serves as the interface between limbic forebrain sites that process
stimuli that threaten the individual and execution of innate affective responses that
enable the individual to cope with the threat (Bernard & Bandler, 1998; Jurgens & Pratt,
1979; Keay & Bandler, 2001).

Inputs from the dmVMH to the dlPAG activate

descending dlPAG projections to the brainstem that coordinate the execution of the
behavioral and autonomic responses that constitute affective responding.

These

projections are activated by nociceptive input to the dmVMH. Neurons within dmVMH
that exhibit Fos expression following presentation of a noxious cutaneous stimulus are
double-labeled by administration of a retrograde tracer into the dlPAG (Parry, et al.,
2002).

Projections from the dlPAG to the rostral ventrolateral medulla initiate the

autonomic reactions associated with affective responses to threats (Lovick, 1992; Wang
& Wessendorf, 2002). Projections from the dlPAG to the nucleus retroambiguus initiate
activity in the laryngeal, articulatory, and respiratory motor neurons that generate
affective vocalizations (Jurgens, 2002).
As depicted in Figure 13, nociceptive input to the CeA activates the dmVMH 
dlPAG  brainstem circuit for generation of VADs. Suppression of VADs that follows
administration of APV into the CeA is posited to reflect inhibition of nociceptive
throughput to the dmVMH and related interconnected limbic sites.

Consequently,

nociceptive input is unable to gain access to the mesolimbic circuit responsible for
generating affective behaviors to threats.

As vocalizations are a common affective

response to imminent threats and exposure to a noxious stimulus is the prototypical
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imminent threat, the interruption of pain input to this circuit suppresses the rat’s affective
vocalizations to pain (i.e., VADs). As Charles Darwin noted concerning the emission of
pain-induced vocalizations (Darwin, 1898):


“When animals suffer from an agony of pain, they generally writhe about with frightful
contortions; and those which habitually use their voices utter piercing cries or groans.”



“Great pain urges all animals, and has urged them during endless generations, to make
the most violent and diversified efforts to escape from the cause of suffering…. As the
muscles of the chest and vocal organs are habitually used, these will be particularly
liable to be acted on, and loud, harsh screams or cries will be uttered.”

4.2 Model of Intra-CeA NMDA-Induced Affective Analgesia
Alternately, elevations in vocalization thresholds following intra-CeA NMDA
administration may reflect the action of this drug at NMDA receptors within the medial
subdivision of the CeA (CeM). Figure 13 depicts excitatory projections from CeM that
activate vlPAG inhibitory projections to the CeALC and dmVMH.

NMDA receptor

activation within CeM is postulated to engage efferent projections of CeM that activate
endogenous antinociceptive mechanisms within the vlPAG. The CeM projects directly
to the vlPAG (Rizvi, Ennis, Behbehani, & Shipley, 1991), a midbrain structure critically
involved in endogenous antinociception.

The neurochemistry of the CeM – vlPAG

projection as involved in antinociception has yet to be elucidated, however, evidence
suggests that substance P may play a role. Substance-P neurons in CeM project to the
vlPAG (Gray & Magnuson, 1992), neurokinin (NK) receptors are localized on vlPAG
enkephalin interneurons (Commons & Valentino, 2002), substance P binding to intravlPAG NK receptors evokes the local release of enkephalin (Drew, Mitchell, & Vaughan,
2005), and activation of vlPAG neurokinin receptors leads to antinociception (Rosen,
Zhang, Lund, Lundeberg, & Yu, 2004).
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Thus, CeM-NMDA receptor activation may activate substance P projections that
interact with the antinociceptive neural circuitry of the vlPAG to produce elevations in
vocalization thresholds. Specifically, the aforementioned substance P induced release
of enkephalin in vlPAG may be the mechanism whereby NMDA administered into the
CeA produced elevations of vocalization thresholds in the present study. The internal
neurochemistry of the vlPAG that contributes to antinociception is well characterized
and is depicted in Figure 12 (Reichling, 1991; Reichling, Kwiat, & Basbaum, 1988). The
vlPAG contains tonically active GABA interneurons that suppress serotonergic output
neurons.

Enkephalin release within the vlPAG inhibits the GABA interneurons via

binding with mu-opiate receptors on the GABA interneurons, thereby disinhibiting
serotonin projection neurons in vlPAG. The serotonergic projection neurons activate
antinociceptive processes at the level of the limbic system, thalamus, and brainstem.
Congruent with this circuitry, morphine administration into the vlPAG and acting at muopiate receptors presumably located on the GABA interneuron, produces elevations in
vocalization thresholds that are blocked via administration of a serotonin receptor
antagonist (methysergide) into the amygdala, medial thalamus, or rostral ventral
medulla (Borszcz, 1995a, 1999).
As noted earlier, behavioral antinociception generated by CeA activation is
blocked by inactivation of the vlPAG via local lidocaine injection or administration of a
mu-opiate receptor antagonist into vlPAG (Leite-Panissi et al., 2003; Oliveira & Prado,
2001).

Further, electrophysiology experiments demonstrated that glutamatergic

stimulation of the CeA alters vlPAG neural activity through intra-vlPAG opiate receptors
(da Costa Gomez & Behbehani, 1995).

Administration of D,L-homocysteic acid, a
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glutamate agonist, into the CeA results in an approximate 1:1 ratio of vlPAG neural
excitation to inhibition. These vlPAG neural responses were suppressed following the
microiontophoretic application of the opiate antagonist naloxone to the vlPAG. The
excitatory and inhibitory responses recorded from the vlPAG may reflect the recording
of separate neural populations in line with the internal neurochemistry of the vlPAG.
Excitatory responses following D,L-homocysteic acid likely reflects excitation of the
vlPAG enkephalin interneurons and/or the serotonergic projection neurons. Alternately,
inhibitory responses likely reflect inhibition of GABA interneurons.
Results of the present study are consistent with the hypothesis that NMDA
receptor activation in CeA suppresses pain affect through the release of enkephalin in
vlPAG, which engages antinociceptive projections from the vlPAG.

Compared to

following injection of saline into the CeA, the administration of NMDA into the CeA
produced increased Fos expression in the vlPAG. This difference in Fos expression
was observed in all three experimental contexts, and therefore is a reliable effect of
NMDA receptor activation within the CeA.

Presumably, Fos was expressed by

enkephalinergic interneurons and serotonergic projection neurons of the vlPAG. This
assumption is supported by the finding that elevations in VAD threshold induced via
bilateral intra-CeA administration of NMDA were reduced following the unilateral intravlPAG administration of the mu-opiate specific antagonist CTAP.
That the vlPAG is involved in producing elevations in vocalization thresholds
following intra-CeA NMDA, but not intra-CeA APV, is also supported by the present
results investigating the expression of Fos-positive nuclei in the vlPAG. Although rats
who received intra-CeA NMDA exhibited greater numbers of Fos-positive nuclei in the
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vlPAG compared to rats administered saline into the CeA, this was not the case with
rats who received APV into the CeA. Fos expression in vlPAG following administration
of APV into the CeA did not differ from that observed following administration of saline
into the CeA. Importantly, the doses of APV and NMDA administered into the CeA
produced significant elevations in vocalization thresholds.

These data suggest that

administration of NMDA into the CeA activates the vlPAG, and the vlPAG contributes to
the elevation of vocalization thresholds produced by intra-CeA NMDA. Conversely,
administration of APV into the CeA does not activate the vlPAG, and thus the vlPAG is
likely not involved in the elevation of vocalization thresholds produced by intra-CeA
APV.
4.3 Interactions of Sub-populations of NMDA receptors in CeA
The results of the present study suggest the NMDA receptors within the CeA are
segregated both anatomically and functionally with regard to the production of
behavioral antinociception. Administration of the NMDA receptor antagonist APV or
agonist NMDA produced a dose-dependent preferential elevation in the threshold of the
VAD response, which is a validated measure of pain affect in the rat. Overall, these
findings indicate that NMDA receptors within the CeA contribute to the processing of
pain affect.

Administration of APV into the CeA likely produces its antinociceptive

effects via the inhibition of nociceptive transmission at the level of the CeALC.
Conversely, the antinociceptive effects elicited via NMDA into the CeA likely are a result
of the activation of CeM projection neurons that engage antinociceptive mechanisms
within the vlPAG.

42
The present finding that NMDA receptor agonism and antagonism within a
particular structure can produce similar effects on nociceptive processing is consistent
with earlier findings of this laboratory. Previously, we reported that administration of
NMDA into the rostral anterior cingulate cortex (rACC) and APV into the caudal ACC
(cACC) both generated dose-dependent increases in vocalization thresholds similar to
that observed in the present study (Greer, 2007). Because the rACC and cACC are
sufficiently separated anatomically, it was possible in that study to separately administer
drugs into either site using our microinjection technique. The CeA, however, is a much
smaller structure and the microinjection technique does not permit the spatial resolution
required to inject APV or NMDA within the boundaries of CeALC or CeM, respectively.
Thus, administration of either drug likely activates both subpopulations of NMDA
receptors.
It is possible to explain the similar behavioral effects of APV and NMDA using a
model that describes the neurochemical and anatomical connections of CeALC and
CeM with structures responsible for the generation of VADs (see Figure 13).
Administration of NMDA into the CeA activates NMDA receptors within the CeALC. It
would be expected that this effect would elicit vocalizations from the rat, given that
activation of the CeALC would engage the neural circuitry (dmVMH and dlPAG)
involved in the generation of VADs (Figure 13, CeALC  dmVMH  dlPAG).
That VADs are not elicited, but rather suppressed, by intra-CeA administration of
NMDA is posited to be the result of concomitant NMDA receptor activation of the CeM.
NMDA receptor activation of CeM is proposed to engage, via mu-opiate mediated
disinhibition, antinociceptive projection neurons from vlPAG that suppress nociceptive
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processing within the circuit that contributes to production of VADs (Figure 13, CeM 
vlPAG  CeALC and dmVMH). Activation of serotonergic neurons of the vlPAG that
project to the CeALC and dmVMH are hypothesized to suppress production of VADs.
Immunohistochemical retrograde transport double labeling studies revealed that
serotonergic neurons in vlPAG project to CeA and VMH (Li, Jia, Rao, & Shi, 1990; Li,
Zeng, Dong, Rao, & Shi, 1991; Smith & Flynn, 1980). Mu-opiate mediated activation of
serotonergic projections to CeA contributes to suppression of VADs. Administration of
the serotonin receptor antagonist methysergide into the CeA reverses the increase in
VAD threshold generated by injection of the mu-opiate receptor agonist morphine into
vlPAG (Borszcz, 1999). This result is consistent with findings that stimulation of vlPAG
or systemic administration of morphine increases the efflux and metabolism of serotonin
in CeA (Spampinato, Esposito, Romandini, & Samanin, 1985; Viana, Graeff, &
Loschmann, 1997). The contribution of serotonergic projections from vlPAG to dmVMH
to the suppression of pain affect has not been evaluated; however, injection of the 5HT1A receptor agonist 8-OH-DPAT into the VMH suppressed defensive vocalizations in
the cat (Hassanain, Bhatt, & Siegel, 2003).
Findings of electrophysiological studies of the amygdala provide additional
support for the hypothesis that serotonergic projections from vlPAG to CeALC inhibit
NMDA receptor mediated nociceptive processing within CeALC. Although no study to
date has investigated the ability of serotonin agonists to suppress NMDA-evoked neural
activity within CeA, several studies suggest such a mechanism.

For example,

microiontophoretic administration of serotonin onto neurons within the lateral amygdala
decreased the number of action potentials elicited via microiontophoretic administration
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of glutamate (Stutzmann & LeDoux, 1999; Stutzmann, McEwen, & LeDoux, 1998). It is
likely that serotonin acts directly within the CeA to inhibit NMDA-induced excitation.
First, 5-HT1A is the primary receptor subtype that mediates post-synaptic serotonin
induced inhibition (see Saxena, 1995). Second, 5-HT1A is the predominate serotonin
receptor found in the CeA (Radja, et al., 1991). In accordance, iontophoretic application
of the 5-HT1A receptor agonist 8-OH-DPAT produced a preferential inhibition of
spontaneous neural activity within the CeA (Stein, Davidowa, & Albrecht, 2000).
Although the effect of serotonin on noxious-evoked unit activity in the amygdala
has not been evaluated, serotonin modulates noxious-evoked activity in the
parafascicular thalamic nucleus (nPF) that is also innervated by serotonergic projections
of the vlPAG (Chen, Zeng, Rao, & Shi, 1992), and contains 5-HT1A and 5-HT7 receptors
(Neumaier, Sexton, Yracheta, Diaz, & Brownfield, 2001; Pazos & Palacios, 1985).
Iontophoretic application of serotonin in the nPF and administration of morphine into the
vlPAG inhibits noxious evoked neural activity in the nPF. These effects were blocked
by local iontophoretic application of the broad-spectrum 5-HT antagonist methysergide
(Dafny, Reyes-Vazquez, & Qiao, 1990; Reyes-Vazquez, Qiao, & Dafny, 1989).
Behavioral antinociception produced by vlPAG-administered morphine was also shown
to be mediated by the activation of serotonin projections to the nPF (Borszcz, 1999;
Borszcz & Streltsov, 2000). Increases in VAD and VDS thresholds generated by the
injection of morphine into vlPAG were reversed in a dose-dependent manner by the
injection of methysergide into nPF. Furthermore, systemic administration of morphine in
a dose that selectively elevates vocalization thresholds increased the release and
metabolism of serotonin in the nPF (Munn & Borszcz, 2002). Direct administration of 8-
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OH-DPAT into the nPF selectively elevated VAD and VDS thresholds, which were
blocked by concurrent administration of the 5-HT1A antagonist WAY 100,635 (Harte, et
al., 2005). These findings support the contention that serotonin acting in the CeALC
may also generate antinociception through inhibition of noxious-evoked activity.
Previous findings from this laboratory demonstrated that increasing mu-opiate
receptor activation in the vlPAG (via injection of increasing doses of morphine)
generates progressive recruitment of serotonergic antinociceptive projections of the
vlPAG that inhibit nociceptive processing at forebrain, medullary and spinal levels of the
neuraxis (Borszcz, 1995a, 1999; Borszcz, Johnson, & Thorp, 1996; Borszcz & Streltsov,
2000).

In the current study, administration of low doses of NMDA into the CeA

presumably only engage antinociceptive projections of vlPAG that inhibit nociceptive
processing at forebrain sites responsible for generating VADs (Borszcz, 2006; Borszcz
& Leaton, 2003; Carroll & Lim, 1960; Hoffmeister, 1968).

As the dose of NMDA

administered into the CeA was increased, VDS threshold was also elevated. VDSs are
organized within the medulla below the pontomedullary border (Carroll & Lim, 1960;
Hoffmeister, 1968).

The effect of NMDA on VDS threshold is likely due to the

recruitment of descending serotonergic projections from the CeA that inhibit nociceptive
processing by medullary neurons responsible for the generation of the VDS response.
Following administration of a dose of morphine into vlPAG that selectively elevated VAD
and VDS thresholds, the subsequent injection of methysergide into the RVM restored
VDS threshold to baseline levels (Borszcz, 1999).
It is well established that mu-opiate receptor activation of vlPAG inhibits
nociceptive processing within the spinal dorsal horn via engaging descending spinopetal
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projections (Basbaum & Fields, 1984; Jensen, 1986; Yaksh & Malmberg, 1994), and
thereby inhibit withdrawal reflexes (tail-flick, paw withdrawal) elicited by noxious stimuli
(Carstens, Hartung, Stelzer, & Zimmermann, 1990; Jensen & Yaksh, 1986; Levy &
Proudfit, 1979; Ossipov, Goldstein, & Malseed, 1984; Yaksh, Yeung, & Rudy, 1976).
Previous studies in this laboratory revealed that vlPAG administration of morphine at
high doses is capable of elevating SMR threshold along with VAD and VDS thresholds.
This increase in SMR threshold is mediated via recruitment of spinopetal projections
from the rostral ventomedial medulla (Borszcz, 1999).

It is conceivable that

administration of a dose of NMDA into the CeA larger than that used in the present
study may indeed elevate SMR threshold. However, there are limitations to the dose of
NMDA that can be administered into the CeA without producing a neurotoxic lesion of
CeA (Maisonnette, et al., 1996).
4.4 Ethological Relevance
The studies presented here provide support for the involvement of NMDA
receptors within subdivisions of the CeA in the generation of affective analgesia. The
perceptual-defensive-recuperative (PDR) theory of fear and pain (Bolles & Fanselow,
1980) provides insight into the ethological relevance of the present findings.

PDR

theory contends that fear will inhibit pain because pain-related behaviors will interfere
with defensive behaviors that occur in response to an imminent predator. For example,
an animal engaged in a physical encounter with a predator and that has sustained an
injury must prevent the emergence of pain-related behavior in order to maintain
execution of defensive behaviors. If the animal were to tend to the injury, the animal
would be rendered defenseless and would provide the predator with an advantage.
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Suppression of pain signaling would allow the animal to devote attention to the predator
rather than to the pain.
Ethological evaluation of the behavior of rodents, other mammals, and humans
revealed that individuals produce a series of defensive behaviors when confronted with
a threat (Blanchard & Blanchard, 1969, 1987; Blanchard, et al., 1986; Fanselow &
Lester, 1988). Proximity of the individual to the threat (i.e., predatory imminence) and
various environmental constraints (availability of escape routes) governs expression of
particular behavior patterns within the series of defensive reactions. For the rat, the
presence of a distant predator results in the cessation of movement (freezing) in order
to make the individual less conspicuous. As a predator approaches and escape routes
are available then rats engage in escape behaviors. When contact with the predator is
imminent and an escape route is not available, rodents engage in defensive aggression
as exemplified by threat-attack behaviors.

The rat rears-up to face the predator,

displays its teeth, and emits sonic vocalizations (see Figure 14). Continued approach
by the predator elicits jump-attacks of the rat upon the predator. Resultant physical
contact with the predator involves continued sonic vocalizations, struggling, biting, and
escape attempts. Defensive aggression serves to thwart the attack of a predator, or to
escape the predator’s grasp or the source of noxious stimulation.
defensive

reactions

include

ultrasonic

vocalizations,

Post-encounter

hyperalgesia,

and

finally

recuperative behaviors.
Evaluation of defensive responding by humans revealed a similar pattern of
defensive behaviors.

The proximity of the subject to the source of threat and the

availability of escape routes determined whether humans engaged in freezing, flight, or

48
defensive aggression (Blanchard, et al., 2001). Human imaging studies that utilized a
virtual maze and virtual predators revealed activation of brain areas consistent with
PDR theory (Mobbs, et al., 2009; Mobbs, et al., 2007). In these studies, participants are
instructed to navigate a virtual maze and evade an approaching virtual predator. If the
predator catches the participant in the maze, the participant will receive noxious shock
to the hand. Functional MRI revealed that as the predator approached an inescapable
distance from the participant, activation of the PAG and CeA occurred that correlated
with post-imaging subjective results of dread (i.e., fear). Furthermore, humans that
received stimulation of sites within the defensive aggression circuit (dorsolateral
periaqueductal gray, medial hypothalamus, amygdala) reported feelings of dread,
anxiety, anger, fear, and impending death (Ervin, et al., 1969; Jenck, Moreau, & Martin,
1995; Nashold, Wilson, & Slaughter, 1974; Tasker, 1982).

The forms of defensive

responding, the environmental variables that determine the pattern of defensive
behaviors, and the underlying neural circuit that generate defensive responding is highly
conserved across mammalian species.
As described above, the neural circuit that governs the execution of defensive
responding to environmental threats is well characterized. The medial hypothalamus
and dlPAG are the core structures of the defense circuit and they are modulated by
inputs from the amygdala (Siegel, 2005).

Environmental stimulus information (for

example, sensory stimuli from a predator, such as a cat) enters the lateral amygdala of
the rat via projections from the sensory thalamus and sensory cortex (LeDoux, 2007).
The thalamic pathway to the amygdala is shorter and thus faster, but its capacity to
represent a potentially threatening stimulus is limited (Bordi & LeDoux, 1994a, 1994b).
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The thalamo-cortico-amygdala pathway, which involves several cortico-cortical links
before reaching the amygdala (Romanski & LeDoux, 1993a, 1993b), is longer and
slower, but provides detailed stimulus information about the threat. The thalamic inputs
thus may be useful for producing rapid defensive responses on the basis of limited
stimulus information. Rapid response to threats has obvious survival value (Ekman,
1992; LeDoux, Cicchetti, Xagoraris, & Romanski, 1990; LeDoux, Iwata, Pearl, & Reis,
1986; Ohman, 1986).

Cortical inputs permit subsequent detailed appraisal of the

stimulus to determine whether in fact it is a threat and the need for continued defensive
responding. Sensory information from the lateral amygdala projects to the basolateral
amygdala (BLA), and the BLA processes the affective salience of stimuli, including fear
and other negative affective states associated with threatening stimuli (Davis & Whalen,
2001; Rosen & Schulkin, 1998). Threat stimuli-induced activation of the BLA activates
projections to CeA, and CeA activation mediates the generation of defensive behaviors
through its projections to the medial hypothalamus and the dlPAG. These defensive
behaviors have a phylogenetic history of enabling the individual to cope with threatening
stimuli (Davis & Whalen, 2001). Because exposure to a noxious stimulus represents an
immediate and intimate threat, defensive behaviors activated under conditions of high
predatory imminence are engaged. The preeminence of noxious stimuli in engaging the
defense circuit is indicated by the fact that noxious stimuli bypass the thalamus and
cortex, and project directly to BLA and CeALC (Bernard & Besson, 1990; Burstein &
Potrebic, 1993; Cliffer, et al., 1991; Gauriau & Bernard, 2002; Li & Neugebauer, 2004a;
Newman, et al., 1996).
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I propose that noxious and non-noxious threats are processed by a common
neural substrate within CeALC to produce defensive responding, and that activation of
CeM modulates this processing so to optimize the animal’s defense against
environmental threats. It is speculated that pain information from the spinal cord and
threat stimulus information from the BLA converge upon the same neural population
within CeALC, and this neural population is responsible for the activation of the dmVMH
and dlPAG, and thereby promotes the execution of defensive responding to noxious
and non-noxious threatening stimuli (see Figure 15). As described earlier, the CeALC
of the rat contains neurons that respond to noxious peripheral stimulation. The CeA of
the rat (along with the LA, BLA, dmVMH and dlPAG) also exhibits neuronal activation in
response to non-noxious threatening stimuli. Beckett and colleagues (1997) reported
that exposure of naïve rats to 20 kHz ultrasonic tone increased Fos expression in all
these sites (Beckett, Duxon, Aspley, & Marsden, 1997b). That is, all components of the
defense circuit are activated. It is well documented that rats emit 22 kHz ultrasonic
vocalizations (USV) when exposed to a predator (Blanchard, Blanchard, Rodgers, &
Weiss, 1990; Knutson, Burgdorf, & Panksepp, 2002). As the production of these calls is
enhanced by the presence of familiar conspecifics (Blanchard, Blanchard, Agullana, &
Weiss, 1991; Brudzynski & Ociepa, 1992), it has been suggested that they provide a
warning signal about an imminent environmental threat.

Accordingly, these

vocalizations (or 22 kHz pure tones) generate defensive responding in rats not directly
exposed to a predator (Brudzynski & Chiu, 1995; Burgdorf, et al., 2008). The defense
circuit is particularly attuned to these vocalizations as a high proportion of neurons in LA
and BLA respond preferentially to acoustic stimuli in the 18 – 27 kHz range (Bordi &
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LeDoux, 1992). Similarly, CeA, dlPAG and dmVMH exhibit enhanced Fos expression in
rats following their exposure to cat odor (Dielenberg, et al., 2001).

The medial

amygdaloid nucleus (MeA), but not LA and BLA, also exhibited increased Fos
expression. This latter finding is consistent with the fact that transmission of odor to
CeA is via the MeA rather than LA and BLA. MeA is considered the ‘vomeronasal
amygdala', the principal limbic projection area of the accessory olfactory bulb (Kevetter
& Winans, 1981; Luiten, Koolhaas, de Boer, & Koopmans, 1985; Martinez-Marcos &
Halpern, 1999; Scalia & Winans, 1975). Therefore, non-noxious threatening stimuli
(auditory or olfactory), like noxious stimuli, appear to gain access to the core structures
of the defense circuit via CeA. The subdivisions of CeA that are activated by nonnoxious stimuli has not been evaluated but it is speculated that CeALC is the principal
target of these stimuli.
The notion that noxious and non-noxious threats are processed by a common
neural substrate within CeALC to produce defensive responding, and that activation of
CeM modulates this processing so to optimize the animal’s defense against
environmental threats, may be explained by the Yerkes-Dodson theory of arousal and
performance (Yerkes & Dodson, 1908). This theory is illustrated with an inverted-U
curve (see Figure 16), which indicates that as arousal increases, efficiency of
performance increases until an optimum level of performance is achieved.

With

increasing arousal past this optimum level, efficiency of performance decreases. In the
case of the rat and the predator cat, predator-stimulus specific information reaches the
MeA (olfaction) and BLA (auditory and visual), which in turn sends excitatory projections
to the CeALC. In turn, the CeALC  dmVMH  dlPAG pathway is engaged and
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defensive responses aimed at thwarting the predator are generated (see Figure 15,
green pathway). If the rat is injured during this confrontation, nociceptive information
will project and add to the cellular activation within CeALC. In terms of Yerkes-Dodson
theory, this extreme compounded cellular activation would drive the rat’s defensive
responding past optimum levels of performance and toward a decreased efficiency in
performance, resulting in the inability for the rat to contend with the predator at optimum
levels. The rat’s behavior would be observed as a compound of defensive strategies to
thwart the predator and strategies to tend to the injury. Such a compound of behaviors
would render the animal unable to devote attention solely to the predator. This would
serve in the predator’s favor because the animal would be unable to contend with the
predator efficiently.
In order to avoid this decreased efficiency in defensive responding to the
predator, it is proposed that the CeALC engages a system that attenuates extreme
levels of cellular arousal within CeALC.

As shown in Figure 15, when nociceptive

projections add to the predator-induced cellular excitation of the CeALC, an intraamygdaloid projection from CeALC  CeM is recruited. The CeM then engages the
endogenous antinociceptive vlPAG serotonergic inhibitory projections that synapse
upon CeALC and dmVMH neurons. This inhibition attenuates the cellular excitation
within the CeALC and dmVMH, and in terms of the Yerkes-Dodson theory, reverses the
performance curve back toward optimum levels.

Thus, the rat is able to contend

effectively with the predator via predator-specific defensive behaviors without
concomitant generation of pain-related behaviors that would interfere with optimum
performance. Lastly, it is proposed that once the rat successfully fights off the predator,
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or the rat is able to escape, the BLA-induced cellular activation of CeALC diminishes,
the vlPAG serotonergic inhibition upon CeALC neurons releases, but the injury-induced
cellular activation of CeALC remains and the rat will engage in pain-related defensive
behaviors designed cope with the injury.
Evidence in support of this model includes studies that have examined the role of
serotonin within the amygdala and medial hypothalamus on defensive aggression and
pain behavior.

Systemic administration of the serotonin agonists buspirone and

gepirone to wild rats significantly reduced defensive aggression (e.g., jump attacks,
sonic vocalizations, biting; Blanchard, Rodgers, Hendrie, & Hori, 1988). Studies on the
anole lizard and mouse, bred for low or high levels of aggression, revealed that high
aggression animals exhibit lower levels of serotonin within the amygdala (medial
nucleus) and the medial hypothalamus (Serri & Ely, 1984; Summers, et al., 2005) and
low aggression animals exhibit higher levels of serotonin within the amygdala (Young, et
al., 2008).

Administration of serotonin into the rat cortical amygdala decreased

defensive aggression measured as a decrease in the number of aggressive
postures/attacks in the shock-induced fighting test (Pucilowski, Plaznik, & Kostowski,
1985). Lastly, injection of the serotonin agonist 8-OH-DPAT into the VMH suppressed
defensive vocalizations in the cat elicited via electrical stimulation of the PAG
(Hassanain, et al., 2003). Studies have investigated the effect of intra-amygdaloid
serotonin administration on pain responses, although no study to date has investigated
this effect within the CeA. Administration of serotonin into the BLA elevates tail-shock
induced vocalization thresholds (Nandigama, 2005), and intra-basomedial amygdala
serotonin administration increases the pressure required to elicit a vocalization in the tail
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compression pain test (Plaznik, Danysz, & Kostowski, 1985). Depletion of forebrain
serotonin via severance of the medial forebrain bundle resulted in analgesia as
measured via flinch-jump, stabilimetric, or hot-plate pain tests, which indicates forebrain
serotonin attenuates pain-related behaviors (Harvey, Schlosberg, & Yunger, 1975).
These studies suggest that increased levels of serotonin within the defensive circuit
suppress defensive aggression and pain behaviors.
4.5 Future Directions
The present study focused on the contribution of intra-CeA NMDA receptors to
the suppression of pain affect. This manuscript put forth the notion that activation of
CeM-NMDA receptors activate endogenous antinociceptive mechanisms via vlPAG muopiate receptors.

Intra-vlPAG administration of CTAP effectively suppressed the

elevations in VAD threshold generated by intra-CeA NMDA administration. The present
study did not assess the capacity of CTAP to alter intra-CeA APV elevations on VAD
thresholds. Given the proposition that APV inhibits nociceptive transmission at the level
of CeALC-NMDA receptors, it is expected that intra-CeA APV-induced elevations in
VADs would not be suppressed by intra-vlPAG CTAP administration. This hypothesis is
supported by the results from the present Fos study, which revealed that Fos levels
within vlPAG are unchanged following intra-CeA APV treatment and indicates that the
vlPAG is not involved in intra-CeA APV-induced elevations in vocalization thresholds.
The neurochemistry underlying nociceptive afferents to CeALC directly via the
spinal cord and indirectly via the pontine parabrachial nucleus and intralaminar
thalamus have yet to be investigated. The present study and others (Li & Neugebauer,
2004a, 2004b) provide evidence that intra-CeA NMDA receptors are implicated in the
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transmission of nociception at the level of the CeALC, but it is not known whether
glutamate is the primary neurotransmitter involved in these ascending projections. In
order to assess whether glutamate is the primary neurotransmitter involved in
ascending nociception to the CeALC, immunocytochemistry studies could be
performed. A potential study may involve labeling of glutamate-containing nociceptive
fibers

to

the

CeA

(e.g.,

spinoamygdaloid,

spinoparabrachioamygdaloid,

or

spinothalamoamygdaloid fibers that respond to noxious stimulation) and receptor
staining of glutamate receptors within CeALC. Contacts of labeled fibers upon stained
glutamate

receptors

would

provide

evidence

that

glutamate

neurotransmitter involved in ascending nociception to CeALC.

is

the

primary

It would also be of

interest to assess whether BLA  CeALC projections that convey non-noxious threat
information also utilize glutamate as the primary neurotransmitter.
In order to bolster the notion that pain information from the spinal cord and nonnoxious threat information from the BLA converge upon the same neural population
within CeALC in order to produce affective responding via the CeA  dmVMH  dlPAG
pathway, single unit recording of CeALC neurons may be evaluated. One such study
may investigate the evoked responses of CeALC neurons to noxious stimuli presented
to the periphery and to non-noxious predator stimuli presented in the environment.
Should a significant number of CeALC neurons respond to both noxious and nonnoxious stimuli, it may be concluded that these forms of threat information converge
upon the same population of neurons within CeALC.
In addition, microdialysis may be used to measure levels of serotonin within
CeALC and dmVMH following administration of NMDA into the CeA. It is predicted that
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following intra-CeA NMDA treatment, levels of serotonin within the CeALC and dmVMH
would increase, reflecting engagement of the CeM  vlPAG circuit that provides
serotonergic inhibition upon the CeALC and dmVMH. Further, it is predicted that APV
treatment of the CeA would not produce increases in serotonin levels in these structures
because APV induced increases in vocalization thresholds is postulated to not rely upon
a vlPAG serotonergic inhibition mechanism.
In terms of the ethological relevance of the present study, it is critical that the
capacity for CeA-administered serotonin to alter pain behaviors and defensive
aggression be evaluated. As previously discussed, serotonin administration into several
amygdaloid structures has been shown to suppress defensive responding and to
suppress pain behaviors, yet these effects have not been demonstrated following
serotonin administration into the CeA.

It would be possible to utilize the tail-shock

vocalization response test and the microinjection technique to assess the capacity of
intra-CeA serotonin to inhibit tail-shock induced vocalizations. Additionally, it would be
possible to use the microinjection technique to administer serotonin into the CeA and
present the rat with a cat in an environment with limited escape routes so as to increase
predatory imminence. It is hypothesized that intra-CeA serotonin would inhibit pain
affect in the form of VADs and inhibit defensive responding in response to the imminent
predator cat.
The ability of intra-CeA serotonin to modulate NMDA-induced cellular excitation
has yet to be evaluated. Electrophysiology experiments may be used to record neural
activity within the CeALC following application of NMDA to the CeALC. It is predicted
that administration of a serotonergic antagonist onto CeALC neurons would suppress
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NMDA-induced neural activity. It would follow that blockade of serotonergic inhibition of
the CeALC and dmVMH would lead to the capacity of intra-CeA NMDA treatment to
elicit defensive behaviors. Thus, administration of a serotonin receptor antagonist to
either CeALC, dmVMH, or both structures followed by intra-CeA NMDA administration
should elicit VAD-like vocalizations and defensive aggression behaviors (e.g., rearing,
biting, jump attacks). With serotonergic receptors blocked, it is predicted that NMDA
would be able to activate the dmVMH  dlPAG neural circuit responsible for the
generation of defensive behaviors.
In summary, exploration of these future directions would provide strong support
for the model presented here regarding the contribution of CeA-NMDA receptors to the
generation of defensive behaviors in response to noxious and non-noxious stimuli.
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Figure 1. Mean (± S.E.M.) threshold current (mA) of spinal motor reflex, (SMR),
vocalization during shock (VDS), and vocalization after-discharge (VAD) of rats who
received bilateral vehicle (saline) and APV microinjections into the central nucleus of the
amygdala (CeA).
* = significantly elevated over vehicle (saline) treatment, p < .05
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Figure 2. Mean (± S.E.M.) threshold current (mA) of spinal motor reflex, (SMR),
vocalization during shock (VDS), and vocalization after-discharge (VAD) of rats who
received bilateral saline and NMDA microinjections into the central nucleus of the
amygdala (CeA).
* = significantly elevated over saline treatment, p < .05
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Figure 3. Schematic depicting the placement of cannulae for the NMDA anatomical
control study. Medial = 1.8mm medial to the central nucleus of the amygdala (CeA).
Central = directly above the CeA. Lateral = 1.8mm lateral to the CeA. Each animal with
a medial, central, or lateral cannula placement receives injections with (A) a 1.8mm
injector, (B) a 3.0mm injector, and (C) a 4.2mm injector.
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Figure 4. Distribution of injection sites within and around the central nucleus of the
amygdala (CeA) that received bilateral injections of NMDA and saline. Black triangles
indicate injection sites from the dose response study where bilateral 1µg NMDA
produced vocalization threshold increases. Black circles indicate injection sites from the
anatomical control study where bilateral 1µg NMDA failed to produce vocalization
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threshold increases (Other-NMDA).

Black squares indicate injection sites from the

anatomical control study where bilateral 1µg NMDA produced vocalization threshold
increases (CeA-NMDA). Coordinates are millimeters posterior to bregma. Figures are
adapted from The Rat Brain in Stereotaxic Coordinates by Paxinos and Watson (1998).
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Figure 5. Comparison of the mean (± S.E.M.) threshold current (mA) of the spinal motor
reflex, (SMR), vocalization during shock (VDS), and vocalization after-discharge (VAD)
of rats produced by the bilateral administration of saline and 1µg NMDA into the CeA
(CeA-NMDA) and sites surrounding the CeA (Other-NMDA).
* = significantly elevated compared to saline treatment, p < .05
† = significantly decreased compared to CeA – NMDA treatment, p < .05
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Figure 6. Mean (± S.E.M.) threshold current (mA) of spinal motor reflex, (SMR),
vocalization during shock (VDS), and vocalization after-discharge (VAD) of rats who
received microinjections of saline or 0.025µg NMDA into the central nucleus of the
amygdala (CeA) and saline or 0.25µg CTAP into the ventrolateral periaqueductal gray
(vlPAG).
* = significantly elevated over sal/CeA + sal/vlPAG, p < .05
† = significantly decreased to NMDA/CeA + sal/vlPAG, p < .05.
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A

B

Figure 7. Distribution of injection sites within (A) the ventrolateral periaqueductal gray
(vlPAG) that received unilateral injections of 0.25µg CTAP and saline and (B) the
central nucleus of the amygdala (CeA) that received bilateral injections of 0.025µg
NMDA and saline.

Coordinates are millimeters posterior to bregma. Figures are

adapted from The Rat Brain in Stereotaxic Coordinates by Paxinos and Watson (1998).

Number of Fos-Positive Nuclei

66

50

saline

45

4μg APV

40

1μg NMDA

35

‡

‡

*

*

30

*

25
20
15
10
5
0
HOME CAGE

CHAMBER ONLY

SHOCK TEST

CONTEXT
Figure 8. Number of Fos-immunoreactive cells in the vlPAG following bilateral
microinjection of saline, APV, or NMDA into the central nucleus of the amygdala (CeA).
Data are expressed as mean±S.E.M. of Fos-positive neurons in a 400µm x 300µm area
of tissue within the vlPAG.
* = significantly elevated over saline, p < .05
‡ = significantly elevated over 4µg APV, p < .05
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A

B

C

Figure 9. Representative vlPAG photomicrographs of Fos-immunoreactive cells (dark
dots) from rats in the Fos expression Home Cage group and treated with bilateral
microinjection of (A) saline, (B) 4µg APV, or (C) 1µg NMDA into the central nucleus of
the amygdala (CeA). Note the greater number of nuclei with dark stain in (C), but not in
(A) or (B). Sections on the left were photographed at 40x, and sections on the right
were photographed at 200x.

68

Mean Threshold Current (mA)

2.50

2.00

saline
4µg APV
1µg NMDA

*
*

*

1.50

*

1.00

0.50

*

*

0.00
SMR

VDS

VAD

Response
Figure 10. Comparison of the mean (± S.E.M.) threshold current (mA) of the spinal
motor reflex, (SMR), vocalization during shock (VDS), and vocalization after-discharge
(VAD) of rats produced by the bilateral administration of saline, 4µg APV, and 1µg
NMDA into the CeA.
* = significantly elevated compared to saline treatment, p < .05
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Figure 11. Representative slices for qualitative analysis of the potential neurotoxic
effects of NMDA administration into the central nucleus of the amygdala (CeA). (A) slice
from a rat that received saline microinjections and (B) slice from a rat that received 1µg
NMDA. Note the lack of tissue blanching surrounding the CeA injection site in (B),
indicating a lack of excitotoxicity. Slices at -1.88mm posterior to bregma.
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Figure 12. Schematic representation of the internal circuitry of the ventrolateral
periaqueductal gray (vlPAG). The vlPAG receives substance P (SP) efferents from the
CeA that likely interact with enkephalin (ENK) neurons. Enkephalin release onto
GABAergic interneurons releases tonic GABA inhibition on the serotonergic (5HT)
projection neurons, resulting in disinhibition of serotonergic (5HT) projection neurons to
limbic, thalamic, and brainstem sites that contribute to the suppression of pain affect
elicited by morphine injected into vlPAG.
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Figure 13. Schematic representation of the neurochemistry leading to inhibition of VAD
responding in APV and NMDA treated rats. APV likely blocks NMDA receptors within
the CeALC, which directly blocks nociceptive transmission from the spinal cord at this
level.

NMDA likely activates NMDA receptors within CeM.

CeM projections (likely

utilizing substance P as a transmitter), activate vlPAG serotonergic projection neurons
that synapse within CeALC to inhibit excitatory responses within this structure. This
mechanism likely prevents any action of NMDA on CeALC NMDA receptors.
Additionally, vlPAG-serotonergic projection neurons synapse within dmVMH. DmVMH
and dlPAG together form the core structures responsible for the generation of VADs.
Presumably, serotonin within dmVMH inhibits excitatory transmission to dlPAG, and
thus VADs are not generated.
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Figure 14. Photograph of a rat engaged in defensive aggression behaviors in response
to an imminent threat, a predator cat. Note that the rat is cornered with limited escape
routes, and the cat is proximal to the rat. The rat is reared-up on its hind limbs and has
its mouth open to bear its teeth and emit sonic vocalizations. From Flynn, 1967.
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Figure 15. Model of noxious and non-noxious input convergence within CeALC on the
generation of defensive aggression. Pain information from the spinal cord and threat
stimulus information from the BLA converge upon the same neural population within
CeALC. This neural population is responsible for the activation of the dmVMH and
dlPAG, which thereby promotes the execution of defensive responding to noxious and
non-noxious threatening stimuli (circuit depicted in green). Compound activation of the
CeALC by noxious (e.g., tail-shock) and non-noxious (e.g., cat) stimuli results in the
recruitment of an intra-CeM excitatory projection to vlPAG. The vlPAG sends inhibitory
serotonergic projections to the CeALC (and dmVMH) that attenuate the intra-CeALC
cellular activation and allows the individual to perform defensive behaviors at an
optimum level of performance.
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Figure 16. Yerkes-Dodson Curve. As arousal increases, efficiency in performance
increases until an optimum level of performance is achieved. With increasing arousal
past this optimum level, efficiency in performance decreases. Based on Yerkes and
Dodson, 1908.
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APPENDIX B
TABLES
Table 1

Descriptive Statistics (Mean ± SEM) of SMR, VDS, and VAD Response Characteristics at Drug Treatment Threshold vs. Saline Threshold

SMR.RT
Latency (ms)

SMR.AMP
Amplitude (mm)

SMR.MAG
Magnitude (cm x ms)

VDS.RT
Latency (ms)

VDS.AMP
Amplitude (dB)

VDS.DUR
Duration (ms)

VAD.RT
Latency (ms)

VAD.AMP
Amplitude (dB)

VAD.DUR
Duration (ms)

309.20 ± 39.79
248.86 ± 96.09
286.57 ± 85.71
400.80 ± 93.88
303.44 ± 50.95

16.03 ± 2.38
27.14 ± 4.59
17.87 ± 5.98
18.80 ± 8.32
19.90 ± 3.54

115.02 ± 16.42
168.40 ± 51.75
97.07 ± 38.98
111.54 ± 36.91
113.37 ± 19.06

295.05 ± 20.58
286.29 ± 84.89
206.86 ± 53.39
255.00 ± 120.21
223.18 ± 26.39

90.06 ± 0.94
87.26 ± 1.97
84.70 ± 1.06
86.53 ± 1.71
85.52 ± 1.22

558.20 ± 22.89
392.29 ± 81.53
310.29 ± 44.09
334.50 ± 57.42
408.45 ± 43.66

1211.50 ± 32.34
1114.86 ± 12.86
1523.60 ± 294.04
1102.00 ± 0.00
1287.14 ± 59.99

86.99 ± 0.79
92.41 ± 2.24
89.96 ± 2.74
87.30 ± 3.20
88.42 ± 1.39

657.20 ± 55.46
747.71 ± 138.11
541.20 ± 176.14
312.00 ± 20.00
606.67 ± 74.88

369.71 ± 108.48
239.75 ± 77.98
179.00 ± 32.75
201.00 ± 47.85

14.59 ± 5.06
26.30 ± 4.61
18.36 ± 5.71
19.01 ± 7.61

111.46 ± 39.07
223.73 ± 56.76
131.49 ± 43.22
141.05 ± 53.42

265.43 ± 26.19
229.25 ± 52.38
256.75 ± 52.37
266.75 ± 38.53

89.81 ± 2.80
90.53 ± 2.62
92.89 ± 2.02
89.34 ± 2.51

510.00 ± 69.80
438.50 ± 72.63
593.25 ± 57.10
432.00 ± 76.39

1102.00 ± 0.00
1351.75 ± 94.85
1239.00 ± 102.45
1379.50 ± 148.50

87.30 ± 2.59
89.76 ± 1.69
87.45 ± 2.41
87.20 ± 1.02

541.43 ± 106.30
685.00 ± 77.62
726.38 ± 169.70
630.00 ± 111.99

306.00 ± 119.41
254.50 ± 98.13
292.00 ± 132.93

25.25 ± 7.83
38.68 ± 13.20
22.15 ± 12.06

202.85 ± 69.59
231.75 ± 95.61
70.35 ± 22.19

247.00 ± 63.43
118.50 ± 14.57
92.00*

89.98 ± 0.54
90.90 ± 3.70
92.70*

476.50 ± 99.49
425.00 ± 65.59
388.00*

1104.00 ± 2.00
1123.33 ± 21.33
---**

89.23 ± 4.67
97.90 ± 1.67
---**

727.50 ± 231.00
347.33 ± 97.24
---**

NMDA Dose Response & Anatomical Control Studies
saline
.1µg NMDA
.25µg NMDA
.5µg NMDA
1µg NMDA

CeA - vlPAG Interaction Study
saline CeA + saline vlPAG
0.025µg NMDA CeA + saline vlPAG
saline CeA + 0.25µg CTAP vlPAG
0.025µg NMDA CeA + 0.25µg CTAP vlPAG

Fos Expression Study - Shock Group
saline
4µg APV
1µg NMDA

* = mean is based on n = 1, see text for details
** = n is equal to zero, see text for details
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Table 2
SMR, VDS, and VAD Response Characteristics at Drug Treatment Thershold vs.
Saline Threshold: ANOVA and Tukey's HSD

Characteristic

F

df

p

Treatment for which Dunnet's
is significant

NMDA Dose Response and Anatomical Control Studies

SMR.RT
SMR.AMP
SMR.MAG
VDS.RT
VDS.AMP
VDS.DUR

0.29
0.81
0.51
1.21
3.18
6.16

4, 83
4, 83
4, 83
4, 79
4, 79
4, 79

0.89
0.53
0.73
0.31
0.02*
0.00*

VAD.RT
VAD.AMP
VAD.DUR

2.26
1.62
0.77

4, 74
4, 74
4, 74

0.07
0.18
0.55

----1μg NMDA/side
0.25μg NMDA/side
0.5μg NMDA/side
1μg NMDA/side
----

3, 30
3, 30
3, 30
3, 30
3, 30
3, 30
3, 30
3, 30
3, 30

0.26
0.58
0.41
0.93
0.75
0.32
0.27
0.76
0.75

----------

0.95
0.57
0.27
0.18
0.9
0.86
0.33
0.19
0.24

----------

CeA - vlPAG Interaction Study

SMR.RT
SMR.AMP
SMR.MAG
VDS.RT
VDS.AMP
VDS.DUR
VAD.RT
VAD.AMP
VAD.DUR

1.40
0.67
1.01
0.15
0.41
1.21
1.37
0.39
0.41

FOS Expression Study - Shock Group

SMR.RT
SMR.AMP
SMR.MAG
VDS.RT
VDS.AMP
VDS.DUR
VAD.RT
VAD.AMP
VAD.DUR

* p < .05

0.05
0.61
1.54
2.38
0.11
0.16
1.15
2.32
1.78

2, 11
2, 11
2, 11
2, 8
2, 8
2, 8
1,6
1,6
1,6
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The amygdala processes stimuli that threaten an individual and organizes the
execution of affective behaviors designed to cope with the threat. The prototypical
threat to an individual is exposure to a noxious stimulus. The central nucleus of the
amygdala (CeA) receives nociceptive afferents and exhibits neuronal activation in
response to noxious peripheral stimulation. NMDA receptors within CeA mediate this
noxious-evoked neural excitation, and previous studies in the laboratory have shown
that blockade of CeA NMDA receptors via the antagonist APV elevates the threshold for
noxious tail-shock-induced vocalization afterdischarges (VADs), a validated measure of
pain affect in the rat. The present study further evaluated the contribution of NMDA
receptors to the suppression of pain affect.
Intra-CeA NMDA receptor activation via the agonist NMDA elevated VAD thresholds
in a dose dependent manner. That the NMDA receptor agonist and antagonist produce
similar behavioral effects is hypothesized as the result of targeting separate neural
populations within the CeA. Whereas the antagonist likely inhibits nociception at the
level of the lateral capsular division of the CeA, the agonist likely activates
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antinociceptive efferents at the level of the vlPAG. In support of this hypothesis, the
present study revealed that Fos expression within vlPAG is greater in rats that received
intra-CeA agonist NMDA treatment compared to those that received the antagonist APV
or saline. Lastly, intra-CeA NMDA agonist-induced elevations in VAD thresholds were
blocked via the pre-treatment of the vlPAG with the mu-opiate antagonist CTAP. These
studies provide the first demonstration of the contribution of CeA NMDA receptors to the
generation of pain affect in the rat.
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